

Kennedy Krieger Institute, Inc. and Affiliates

**Reports on Federal Awards in Accordance with
Uniform Guidance**

June 30, 2019

Federal Entity Identification Number 52-1524965

Kennedy Krieger Institute, Inc. and Affiliates

Index

June 30, 2019

	Page(s)
Part I - Financial Statements and Schedule of Expenditures of Federal Awards	
Report of Independent Auditors	1–2
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	4
Consolidated Statements of Cash Flows.....	5
Notes to Consolidated Financial Statements	6–36
Report of Independent Auditors	37
Supplemental Combining Financial Statements	38–42
Schedule of Expenditures of Federal Awards	43–57
Notes to Schedule of Expenditures of Federal Awards	58
Part II - Reports on Compliance and Internal Control	
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	60–61
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the OMB Uniform Guidance	62–63
Part III – Schedule of Findings and Questioned Costs	
Schedule of Findings and Questioned Costs	65–66
Part IV – Summary Schedule of Prior Audit Findings	
Summary Schedule of Prior Audit Findings	68

Part I
Financial Statements and
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2019



Report of Independent Auditors

To the Board of Directors of
Kennedy Krieger Institute, Inc. and Affiliates:

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute"), which comprise the consolidated balance sheets as of June 30, 2019 and 2018, and the related consolidated statements of operations, changes in net assets and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Institute's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Kennedy Krieger Institute, Inc. and Affiliates as of June 30, 2019 and 2018, and the consolidated changes in their net assets and cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2019 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we have also issued our report dated September 25, 2019 on our consideration of the Institute's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2019. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Institute's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

Baltimore, Maryland
September 25, 2019

Kennedy Krieger Institute, Inc. and Affiliates
Consolidated Balance Sheets
As of June 30, 2019 and 2018
(in thousands)

	2019	2018
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 9,050	\$ 15,407
Patient receivable, less allowances of \$ 5,016 and \$5,529	24,742	22,313
Grant and contract receivable	4,825	5,048
Tuition receivable	4,201	6,094
Pledges receivable	2,656	9,038
Investments limited as to use	-	7,676
Prepaid expenses and other	2,547	2,183
Total current assets	<u>48,021</u>	<u>67,759</u>
Non-current assets:		
Property and equipment, net	161,827	145,234
Investments:		
Long-term investments	56,576	55,915
Investments limited as to use	8,261	7,765
Pledges receivable, less allowances of \$2,234 and \$2,208	1,701	3,763
Total non-current assets	<u>228,365</u>	<u>212,677</u>
Total assets	<u>\$ 276,386</u>	<u>\$ 280,436</u>
LIABILITIES AND NET ASSETS		
Current liabilities:		
Accounts payable and accrued expenses	\$ 35,743	\$ 34,107
Deferred grant revenue	1,738	2,210
Line of credit	1,000	-
Current portion of tax-exempt bonds	3,204	3,125
Total current liabilities	<u>41,685</u>	<u>39,442</u>
Long-term liabilities:		
Tax-exempt bonds, net	77,247	80,403
Accrued pension	18,955	14,740
Interest rate swap	8,359	6,320
Other long-term liabilities	4,249	3,924
Total long-term liabilities	<u>108,810</u>	<u>105,387</u>
Total liabilities	<u>150,495</u>	<u>144,829</u>
Net assets:		
Without donor restrictions	101,591	99,783
With donor restrictions	24,300	35,824
Total net assets	<u>125,891</u>	<u>135,607</u>
Total liabilities and net assets	<u>\$ 276,386</u>	<u>\$ 280,436</u>

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Consolidated Statements of Operations and Changes in Net Assets
As of June 30, 2019 and 2018
(in thousands)

	2019	2018
Operating revenues:		
Patient service revenue, net of contractual allowances	\$ 176,977	\$ 170,593
Bad debt expense	(3,630)	(4,428)
Net patient service revenue	173,347	166,165
Tuition revenue	47,753	48,944
Grant and contract revenue	35,010	33,949
Net assets released for operating activities	6,441	3,819
Investment earnings used for operating activities	2,040	2,022
Contributions from fundraising activities, net	1,551	1,623
Other operating revenues	1,161	1,573
Total operating revenues	267,303	258,095
Operating expenses:		
Salaries, wages and benefits	202,227	191,473
Supplies, purchased services, and other	49,474	49,356
Depreciation and amortization	9,965	9,214
Rent	2,572	2,800
Interest	2,530	1,882
Total operating expenses	266,768	254,725
Operating revenues over operating expenses	535	3,370
Non-operating activity:		
Investment return, net	1,079	3,140
Realized and unrealized gain(loss) on interest rate swap	(2,778)	1,271
Restricted fundraising expenses	(1,168)	(1,185)
Net non-operating activities	(2,867)	3,226
Excess of revenue (under) over expenses	\$ (2,332)	\$ 6,596
Net assets without donor restrictions:		
Excess of revenue (under) over expenses	\$ (2,332)	\$ 6,596
Net assets released from restriction for property and equipment	10,340	5,005
Change in funded status of defined benefit plan	(6,200)	1,927
Increase in net assets without donor restrictions	1,808	13,528
Net assets without donor restrictions, beginning of year	99,783	86,255
Net assets without donor restrictions, end of year	\$ 101,591	\$ 99,783
Net Assets with donor restrictions:		
Contributions	\$ 5,257	\$ 6,620
Net assets released from restrictions for operations	(6,441)	(3,819)
Net assets released from restrictions for property and equipment	(10,340)	(5,005)
Decrease in net assets with donor restrictions	(11,524)	(2,204)
Net assets without donor restrictions, beginning of year	35,824	38,028
Net assets without donor restrictions, end of year	\$ 24,300	\$ 35,824
(Decrease) increase in total net assets	\$ (9,716)	\$ 11,324
Total net assets, beginning of year	135,607	124,283
Total net assets, end of year	\$ 125,891	\$ 135,607

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Consolidated Statements of Cash Flows
For the Years Ended June 30, 2019 and 2018
(in thousands)

	2019	2018
Cash flows from operating activities:		
Change in net assets	\$ (9,716)	\$ 11,324
Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities:		
Net realized and unrealized (gains) on investments, net	(466)	(3,490)
Depreciation and amortization	9,965	9,214
Bad debt expense	3,630	4,428
Change in pension liability, net	4,215	(3,453)
Change in valuation of interest rate swap	2,039	(2,225)
Contributions restricted for long-term purposes	(6,399)	(6,881)
Changes in assets and liabilities:		
Patient receivables	(6,060)	(8,930)
Other receivables	10,560	4,933
Prepaid expenses	(363)	(619)
Accounts payable and accrued expenses	1,635	3,017
Deferred grant revenue	(472)	303
Other liabilities	892	311
Net cash provided by operating activities	<u>9,460</u>	<u>7,932</u>
Cash flows from investing activities:		
Purchase of property and equipment	(26,558)	(30,249)
Net sales of investments	(195)	(198)
Draws on construction funds, net	7,676	17,267
Other changes in assets limited to use	(496)	(515)
Net cash (used in) investing activities	<u>(19,573)</u>	<u>(13,695)</u>
Cash flows from financing activities:		
Payments on tax-exempt bonds	(3,077)	(2,305)
Proceeds from line of credit	31,750	8,800
Payments on line of credit	(30,750)	(8,800)
Payments on capital lease obligation	(566)	(361)
Proceeds from contributions restricted for long-term purposes	6,399	6,881
Net cash provided by financing activities	<u>3,756</u>	<u>4,215</u>
Net increase (decrease) in cash and cash equivalents	<u>(6,357)</u>	<u>(1,548)</u>
Cash and cash equivalents, beginning of year	<u>15,407</u>	<u>16,955</u>
Cash and cash equivalents, end of year	<u>\$ 9,050</u>	<u>\$ 15,407</u>
Cash paid during the year for interest	\$ 2,530	\$ 1,882
Purchases of property and equipment in accounts payable	2,037	2,992

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
For the Years Ended June 30, 2019 and 2018
(in thousands)

1. DESCRIPTION OF ORGANIZATION

Kennedy Krieger Institute, Inc. and Affiliates (the “Institute”) is an internationally recognized organization dedicated to improving the lives of children, adolescents and young adults through comprehensive patient care, education and research. The Institute’s primary operating activities include healthcare services, research, training, special education and fundraising.

The operations of the Institute are carried out through a number of legal corporate entities. The consolidated financial statements of the Institute reflect the accounts of the following separate legal corporate entities:

- Kennedy Krieger Institute, Inc.
- Kennedy Krieger Children’s Hospital, Inc.
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Kennedy Krieger Education and Community Services, Inc.
- Kennedy Krieger Associates, Inc.
- PACT: Helping Children with Special Needs, Inc.
- Kennedy Krieger Foundation, Inc.
- Madison Street Properties, Inc.

Healthcare services are provided through Kennedy Krieger Children’s Hospital, Inc. and include a forty-five bed inpatient unit admitting more than 350 patients yearly, over fifty specialty outpatient clinics generating in excess of 204,500 annual visits and the training of over 400 healthcare professionals each year. Net patient service revenue generated through Healthcare activities represents approximately 64.9% and 64.4% of the Institute’s operating revenue in fiscal years 2019 and 2018, respectively.

Studies conducted through Research activities within the Hugo W. Moser Research Institute at Kennedy Krieger, Inc. are provided through over 217 government and private awards. Research grant and contract revenue represents approximately 13.1% and 13.2% of the Institute’s operating revenue in fiscal years 2019 and 2018, respectively. Approximately 74.9% and 78.1% of this revenue in fiscal years 2019 and 2018, respectively, comes from departments and agencies of the United States government. Major government sponsors included the Department of Health and Human Services, the Department of Defense and the Department of Justice.

Special education services provided through Kennedy Krieger Education & Community Services, Inc. are conducted through non-public special education schools for students from kindergarten to grade eight, high school, specialized autism programs and partnership programs within public schools. Tuition and related contractual revenue generated through special education services represents approximately 17.9% and 19.0% of the Institute’s operating revenue in fiscal years 2019 and 2018, respectively.

Kennedy Krieger Institute, Inc. and Affiliates

Notes to Consolidated Financial Statements

As of June 30, 2019 and 2018

(in thousands)

Kennedy Krieger Institute, Inc., Kennedy Krieger Children's Hospital, Inc., Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Kennedy Krieger Education and Community Services, Inc., Kennedy Krieger Associates, Inc., and PACT: Helping Children with Special Needs, Inc. are Maryland non-stock corporations organized for charitable, scientific and educational purposes and are tax-exempt under Section 501(c)(3) of the Internal Revenue Code. Kennedy Krieger Foundation, Inc. (the "Foundation"), is a Maryland stock corporation and is tax-exempt under Section 501(c)(3) of the Internal Revenue Code.

Madison Street Properties, Inc. ("MSP") is a tax-exempt supporting organization under Section 509(a)(3) of the Internal Revenue Code and is wholly owned by the Foundation. All real and personal property and leasehold rights owned by the Institute are held by MSP, that in turn leases or subleases the property back to each member of the corporate family utilizing it and also provides property management services, including maintenance, security and housekeeping.

The Institute maintains an independent affiliation with The Johns Hopkins University. The formal relationship between the parties is set forth in an affiliation agreement whereby (i) the medical, scientific and other professional staff of the Institute receive primary and adjunct appointments in the appropriate Johns Hopkins University Schools or departments; and (ii) each Institution's independent corporate status is retained. Goods and services are purchased and sold by each organization through arms length transactions.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements of the Institute have been prepared on the accrual basis, which conforms to accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Institute after elimination of all significant intercompany accounts and transactions.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include investments in highly liquid instruments with original maturities of three months or less. These investments are carried at cost, which approximates market value.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

Investments and Investment Income

Investments in equity securities with readily determinable fair values and all investments in debt securities are classified as trading and are recorded at fair value in the Consolidated Balance Sheets.

Investment income is included in the non-operating activity section of the Statement of Operations. Investment income includes interest and dividends, realized and unrealized gains (losses) on investments.

Allowance for Doubtful Accounts

An allowance for doubtful accounts is recorded for patient receivables which are anticipated to become uncollectible in future periods. Receivables deemed to be uncollectible have been written off.

Grant and Contract Revenue and Receivable

Grant and contract revenues are recorded through cost reimbursement arrangements when allowable costs are incurred, through service rates as services are provided or when contractual terms are satisfied. Grant and contract receivables are recorded when earned. A reserve for uncollectible accounts has been estimated and recorded against grant and contract receivables.

Tuition Revenue and Receivable

Tuition revenue is recognized when earned over the school term (July to June). Tuition receivables are recorded when earned. The Institute does not record an allowance as tuition is paid in full by the local education agencies of the State of Maryland at state approved tuition rates.

Pledges Receivable

Unconditional promises to give cash and other assets to the Institute are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the commitment is received in writing.

Pledges receivable from capital campaigns and other contributions, have been recorded net of an allowance for uncollectible pledges. The allowance for uncollectible pledges receivable is estimated based on the nature and source of each pledge including pledge payment history and the donor's likelihood of honoring the commitment. The allowance is applied to pledges greater than one year. Multi-year pledges are recorded at their estimated present value using a risk-free rate of return of 3.5% and 4% for 2019 and 2018, respectively.

Excess of Revenue over Expenses

The Statements of Operations include excess of revenues over (under) expenses, which is the Institute's performance indicator. Changes in net assets without donor restrictions, which are excluded from excess of revenues over expenses consistent with industry practice, include unrealized gains and losses on investments, certain pension related

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

transactions and assets acquired using contributions which by donor restrictions were to be used for the purpose of acquiring such assets.

Investments Limited as to Use

Investments limited as to use primarily include assets held by trustees under bond indentures, self-insurance trust arrangements, deferred compensation plans and other restricted gift arrangements.

Property and Equipment

Property and equipment acquisitions are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives:

Buildings and Improvements	30–40 years
Fixed Equipment	10–15 years
Computer Software	10–15 years
Furniture and Equipment	3–5 years

Equipment purchases under grants, where title to the equipment rests with the grantor, are recorded as expenditures of the grant and are not capitalized or depreciated.

Capital Leases

Capital leased assets are amortized over the shorter of their estimated useful lives or the lease term. Depreciation expense on capitalized leased assets is included in depreciation and amortization expenses in the Consolidated Statements of Operations.

Deferred Financing Costs

Costs incurred related to the issuance of bonds payable have been deferred and are being amortized over the life of the bonds using the effective interest method. In fiscal year 2017, the Institute adopted ASU 2015-03, "Simplifying Presentation of Debt Issuance Costs". These debt issuance costs are now presented as a deduction from the carrying value of the associated debt.

Accrued Expenses

Accrued expenses are operating expenses that have been incurred but which have not been paid as of the balance sheet date. These expenses are typically periodic and due within one year or less. They include expenses incurred for payroll, employee benefits, subcontracts, interest and other operating items.

Deferred Grant Revenue

Deferred grant revenue has been recorded to reflect the portion of cash received on awarded grants where the grantor restrictions for its use have not been satisfied. Typically, the donor restrictions are satisfied within a year, therefore, deferred grant revenue is classified as a current liability.

Net Assets

Net assets without donor restrictions include undesignated amounts as well as amounts designated by the Board for a specific purpose. Net assets with donor restrictions are

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

held by the Institute and consist primarily of amounts contributed to the Institute by donors with purpose restrictions. The Institute also has net assets with donor restrictions that are perpetual in nature. Earnings on these assets are available for use as specified by the donors.

Estimated Professional and General Liability Costs

The provision for estimated professional and general liability claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

Derivatives

The use of derivatives by the Institute is generally limited to interest rate swaps. The Institute follows accounting guidance on derivative financial instruments that are based on whether the derivative instrument meets the criteria for designation as cash flow or fair value hedges. The criteria for designating a derivative as a hedge include the assessment of the instrument's effectiveness in risk reduction, matching of the derivative instrument to its underlying transaction, and the assessment of the probability that the underlying transaction will occur. The Institute's only derivative financial instrument is an interest rate swap agreement without hedge accounting designation.

The Institute recognizes its interest rate swap as a liability on the Consolidated Balance Sheet at fair value. The change in the value of this derivative is recorded as an unrealized gain or loss in the Consolidated Statements of Operations.

Pension Plans

The Institute follows current technical guidance for reporting and accounting for pension benefits provided to employees. This guidance requires recognition of the funded status of a defined benefit plan in the balance sheet as an asset or liability if the plan is over funded or underfunded, respectively. Changes in the funded status of a plan are required to be recognized in the year in which the changes occur through changes in unrestricted net assets. The guidance also requires the measurement date of the plan's funded status to be the same as the company's fiscal year end.

Short-term Investments

Short-term investments are carried at fair value and are comprised of instruments with an average duration of 1 to 3 years.

Investments

The fair values for marketable equity, government, and fixed income securities included in long-term investments are based on quoted market prices. Alternative investments, which are not readily marketable, are carried at estimated fair values as provided by the investment managers and are valued at the latest available unaudited net asset value of the investments.

Long-term Debt Obligations

Management estimates that the fair value of long-term debt is equal to its carrying value.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

Reclassifications

Certain reclassifications have been made to conform with the current year financial statement presentation.

New Accounting Pronouncements

In May 2014, the FASB issued a standard on Revenue from Contracts with Customers. This standard implements a single framework for recognition of all revenue earned from customers. This framework ensures that entities appropriately reflect the consideration to which they expect to be entitled in exchange for goods and services by allocating transaction price to identified performance obligations and recognizing revenue as performance obligations are satisfied. Qualitative and quantitative disclosures are required to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The standard is effective for fiscal years beginning after December 15, 2018. The Institute is evaluating the impact this will have on the consolidated financial statements beginning in fiscal year 2020.

In August 2016, the FASB issued ASU 2016-14 "Presentation of Financial Statements of Not-for-Profit Entities". The new guidance requires improved presentation and disclosures to help not-for-profits provide more relevant information about their resources to donors, grantor, creditors and other users. Kennedy Krieger Institute adopted this presentation in fiscal year 2019 and retroactively applied the standard to fiscal year 2018.

In January 2016, the FASB issued ASU 2016-01, "Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities". ASU 2016-01 addresses accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Non-public business entities will no longer be required to disclose the fair value of financial instruments carried at amortized cost. The amendments in ASU 2016-01 are effective for years beginning after December 15, 2018, and early adoption is permitted. The Institute is evaluating the impact of this update on consolidated financial statements beginning in fiscal year 2020.

In February 2016, the FASB issued ASU 2016-02 "Leases". This standard requires lessees to recognize assets and liabilities for the rights and obligations created by leases with terms in excess of 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease will primarily depend on its classification as a finance or operating lease. The accounting by lessors remains largely unchanged. This standard is effective for fiscal years beginning after December 15, 2019. Kennedy Krieger Institute is evaluating the impact this will have on the consolidated financial statements beginning in fiscal year 2021.

In June 2018, the FASB issued ASU 2018-08, "Not-for-Profit Entities (Topic 958), Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made". The new standard applies to all entities that receive or make contributions. The guidance clarifies the definition of transactions accounted for as an exchange transaction subject to ASU 2014-09 or other applicable guidance, and

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

transactions that should be accounted for as contributions (non-exchange) subject to the contribution accounting model. Further, the guidance provides criteria for evaluating whether contributions are unconditional or conditional. Conditional contributions must specify a barrier that the recipient must overcome and a right of return that releases the donor from its obligation if the barrier is not achieved, otherwise the contribution is unconditional. The update is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Institute is evaluating the impact of this update on consolidated financial statements beginning in fiscal year 2020, and believes there will be no significant impact.

3. **NET PATIENT SERVICE REVENUE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS**

Net patient service revenues from inpatient and outpatient services are reported at estimated net realizable amounts from patients, third-party payors, and others for services rendered including estimates for contractual allowances with third-party payors and bad debts.

The Institute has agreements with third-party payors that provide for payments to the Institute at amounts different from its established rates. Net patient service revenue is comprised of the following:

	2019	2018
Gross Inpatient Revenue	\$ 61,271	\$ 59,850
Less: Contractual Allowances	(12,927)	(11,482)
Bad Debt Expense	(357)	(703)
Net Inpatient Revenue	<u>47,987</u>	<u>47,665</u>
Gross Outpatient Revenue	143,513	135,857
Less: Contractual Allowances	(14,880)	(13,632)
Bad Debt Expense	(3,273)	(3,725)
Net Outpatient Revenue	<u>125,360</u>	<u>118,500</u>
Net Patient Service Revenue	<u>\$ 173,347</u>	<u>\$ 166,165</u>

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

The percentage of patient service revenue generated by payor category for the fiscal years ended June 30, 2019 and 2018 is as follows:

	2019	2018
Medicaid	33 %	35 %
Blue Cross	23 %	23 %
Commerical	24 %	25 %
Commercial Managed Care	16 %	14 %
Self pay and other	2 %	1 %
Medicare	2 %	2 %
	<u>100 %</u>	<u>100 %</u>

The Allowance for Doubtful Accounts is based upon management's assessment of historical and expected net collections considering trends in healthcare coverage, economic conditions and payor mix. Management assesses the adequacy of the allowance periodically based upon historical collection and write off experience. After collection of amounts due from insurers, the Institute follows internal guidelines for placing certain past-due balances with collection agencies.

	2019	2018
Beginning Allowance for doubtful accounts	\$ 5,529	\$ 4,715
Plus: Bad debt expense	3,630	4,428
Less: Bad debt write-offs, net of recoveries	<u>(4,143)</u>	<u>(3,614)</u>
Ending Allowance for doubtful accounts	<u>\$ 5,016</u>	<u>\$ 5,529</u>

A summary of the payment arrangements with major third-party payors and patient financial assistance follows.

Maryland Medicaid

Since January 1, 2007 the Institute has been under a prospective payment system ("PPS") with Maryland Medicaid for both inpatient and outpatient services. Service-based per diem rates for inpatient services are annually adjusted by market basket update factors published by the Centers for Medicare and Medicaid Services ("CMS"). Outpatient services are reimbursed as a percentage of charges and subject to the lower of cost versus charges. Base year costs are trended forward annually using the CMS outpatient PPS market basket update factor and compared to actual charges. No retroactive settlement occurs under these arrangements.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

Out of State Medicaid

The Institute has entered into payment agreements with many out-of-state Medicaid Plans. The majority of these payment agreements reflect similar rates paid by Maryland Medicaid. No retroactive settlement occurs under these agreements.

Commercial Insurance

The Institute has also entered into payment agreements with commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis of payment to the Institute under these agreements includes prospectively determined rates per day or discharge, discounts from established charges and prospectively determined daily rates. No retroactive settlement occurs under these agreements.

Medicare

Certain inpatient and outpatient services rendered to Medicare beneficiaries are subject to retrospective cost-based reimbursement. Medicare cost reports have been filed through 2018 and final settled through 2016. No significant settlement due to or from the Medicare Program has been estimated and as a result no receivable or payable has been recorded at June 30, 2019 or 2018.

Financial Assistance and Community Benefit

The Institute provides services without charge or at discounted charges to patients who meet certain criteria under its financial assistance policy. The criteria for financial assistance considers the patient or patient's family's ability to pay at time of service. The Institute uses the federal poverty guidelines to determine eligibility for free care or discounted care. In addition, the Institute's policy applies to patients who are medically indigent. The Institute also offers payment plan options to assist patients who experience a financial hardship paying their hospital and professional services bills, but who might not qualify for financial assistance. In January 2016, the Institute expanded its financial assistance policy along with developing a plain language summary of the policy that is distributed to patients at registration.

The cost for services and supplies furnished under the Institute's financial assistance policy aggregated approximately \$1,133 and \$1,079 in 2019 and 2018, respectively. The cost has been estimated based on a cost to charge ratio and applied to financial assistance charges.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

In addition to patient financial assistance and payment plan options, the Institute provides various community benefits across the developmental disability populations within the State of Maryland. The foundation of its community benefits envisions that all persons with developmental disabilities ("DD") lead fully inclusive and meaningful lives. A community needs assessment was conducted and is periodically updated to understand the needs of the community served. Based on the needs assessment, the Institute promotes and hosts educational forums, provides respite care resources, acts as a resource finder, provides advocacy and legal services, promotes and arranges information exchange among patients, families and professionals, promotes workforces development, is a leader in healthcare training in DD, and conducts research, among other things.

4. TUITION REVENUE

Tuition revenue generated by school programs is summarized as follows:

	2019	2018
High school	\$ 15,370	\$ 14,765
Lower/middle school	14,252	14,026
Leap/Autism	7,377	7,426
Montgomery County	7,751	6,642
Partnership programs	2,302	5,373
PACT daycare	639	659
Other	62	53
	<u>\$ 47,753</u>	<u>\$ 48,944</u>

Over 570 students are enrolled in special education programs each year and come from fourteen Maryland counties, Washington, D.C. and other sources. The percentage of tuition revenue generated by jurisdiction is as follows:

	2019	2018
Prince George's County, MD	26.0 %	22.3 %
Other MD Counties	18.9 %	18.4 %
Baltimore County, MD	16.0 %	14.3 %
Anne Arundel County, MD	14.6 %	12.8 %
Montgomery County, MD	9.6 %	8.3 %
Washington, DC	7.1 %	5.9 %
Baltimore City, MD	6.9 %	17.4 %
Other	0.9 %	0.6 %
Total	<u>100.0 %</u>	<u>100.0 %</u>

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

5. GRANT AND CONTRACT REVENUE

Grant and contract revenue is generated through the following activities:

	2019	2018
Research	\$ 26,312	\$ 26,130
Community service	6,474	6,177
Training	2,224	1,642
	<u>\$ 35,010</u>	<u>\$ 33,949</u>

Research revenue includes all research initiatives funded through government and private sources. Community service revenue consists of services provided to individuals and families with special needs in a community-based setting and is funded through government programs. Training revenue represents government funding of training programs for professionals in the field of developmental disabilities.

Grant and contract revenue includes recoveries of facility and administrative costs, with certain limitations and exclusions. Certain revenues and costs in current and prior years are subject to audit and retroactive settlement. No reserve has been recorded for any potential settlements as amounts are not known or are considered immaterial.

6. CONTRIBUTIONS FROM FUNDRAISING ACTIVITIES

During 2019 and 2018, the Institute recognized contributions from fundraising activities as summarized below:

	2019	2018
Contributions		
With donor restrictions	\$ 5,257	\$ 6,620
Without donor restrictions	1,551	1,623
Total Contributions	<u>\$ 6,808</u>	<u>\$ 8,243</u>
Fundraising expenses		
Without donor restrictions	\$ 1,707	\$ 2,015
With donor restrictions	1,168	1,185
Total Expenses	<u>\$ 2,875</u>	<u>\$ 3,200</u>

Contributions with donor restrictions are made up of annual giving and capital campaign contributions which are classified as net assets with donor restrictions on the Consolidated Balance Sheets. Contributions that are donor restricted to be held in perpetuity reflect gifts where the corpus cannot be utilized but where investment earnings are available for use. These contributions are also classified as net assets with donor

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

restrictions on the Consolidated Balance Sheets. Contributions that reflect gifts with no donor restrictions are reported on the Consolidated Statements of Operations.

Fundraising expenses are reported as operating expenses for those expenses related to unrestricted contributions and non-operating expenses for those expenses related to restricted contributions. Expenses related specifically to special events are netted with the revenue from those events.

7. INVESTMENTS AND INVESTMENT INCOME

Investments at June 30, 2019 and 2018 consist of the following:

	2019	2018
Long-term investments		
Fixed income mutual funds	\$ 17,211	\$ 16,251
Equity mutual funds	39,365	39,156
Absolute return fund	-	508
Total long- term investments	<u>56,576</u>	<u>55,915</u>
Investments limited as to use		
Money market funds	635	7,701
Fixed income mutual funds	1,908	2,077
Equity securities and funds	5,718	5,663
Total assets limited to use	<u>8,261</u>	<u>15,441</u>
Total Investments	<u>\$ 64,837</u>	<u>\$ 71,356</u>

Changes in Long-term investments for the years ended June 30, 2019 and 2018 are as follows:

	2019	2018
Long-term investments, beginning of year	\$ 55,915	\$ 52,227
Investment return, net	2,692	4,700
Investment earnings appropriated for expenditure	(2,040)	(2,022)
Investment earnings payable for expenditure	9	1,010
Long-term investments, end of year	<u>\$ 56,576</u>	<u>\$ 55,915</u>

The Investment Committee of the Board of Directors ("Investment Committee") sets the investment policy for the long-term investments, including investment and spending guidelines. Investments of the long-term investments are based on the objective of achieving capital appreciation and investment income. Assets are invested in a manner that is intended to achieve an average annual real return in excess of inflation while

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

assuming an acceptable level of investment risk. To monitor the effectiveness of the investment strategy of long-term investments, performance goals are established and monitored related to benchmark indices and returns earned by comparable funds.

To satisfy its long-term rate of return objectives of the long-term investments, the Institute employs a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current income (interest and dividends). The investment policy includes a target asset allocation that is well diversified among suitable asset classes and that is expected to generate, on average, the level of expected return necessary to meet the long-term investments' objectives while assuming a level of risk (volatility) consistent with achieving that return.

The asset allocation of the Long-term investments at June 30, 2019 and 2018 is summarized below. The Investment Committee regularly reviews the actual asset allocation against the target and periodically rebalances the investment, as appropriate.

	Target Allocation	Actual Allocation	
		2019	2018
Equities	70%	70%	70%
Fixed income	30%	30%	29%
Absolute return funds	0	0	1%
	<u>100%</u>	<u>100%</u>	<u>100%</u>

The investment policy also provides for a long-term investment earnings withdrawal to be used in support of operating activities, as determined by Institute management and approved through the annual budget. The annual withdrawal is determined based on 4% of the three-year average market value of the portfolio. Withdrawals of \$2,031 and \$1,012 were made in 2019 and 2018, respectively to fund operating needs and have been reported as operating revenues.

Investments with a market value of \$1,417 and \$1,391 as of June 30, 2019 and 2018, respectively have been pledged as collateral under the Institute's self-funded unemployment insurance plan.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

Investments Limited As To Use

Investments limited as to use at June 30, 2019 and 2018 are made up of the following:

	2019	2018
Construction funds	\$ -	\$ 7,675
Self insurance trust fund	4,486	4,212
Deferred compensation	2,104	1,949
Donor restricted fund	1,091	1,045
Planned gifts, net of reserve	285	265
Donor advised fund	295	295
	<hr/>	<hr/>
Total investments limited as to use	8,261	15,441
Less: Current portion	-	7,676
	<hr/>	<hr/>
Long-term portion	\$ 8,261	\$ 7,765
	<hr/>	<hr/>

Investment Income and Gains and Losses

Investment income and gains and losses are comprised of the following:

	2019	2018
Investment income		
Interest and dividend income	\$ 2,443	\$ 1,671
Realized gain on investments, net	467	694
Less: Investment earnings appropriated for operating activities	(2,040)	(2,022)
	<hr/>	<hr/>
Net investment income	\$ 870	\$ 343
	<hr/>	<hr/>
Net unrealized gain on investments	\$ 209	\$ 2,796
	<hr/>	<hr/>

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

Liquidity and Availability

Financial assets at June 30, 2019 are made up of the following:

Cash	\$ 9,050
Patient receivable, net	24,742
Grant and contract receivable	4,825
Tuition receivable	4,201
Pledges receivable, net	4,357
Prepaid expenses and other current assets	2,547
Investments limited as to use	8,261
Long-term investments	56,576
Total financial assets	<u>114,559</u>
Less amounts not available:	
Investments limited as to use	8,261
Pledges receivable, in excess of 1 year	1,701
Financial assets not available to be used within one year	<u>9,962</u>
Financial assets available to meet general expenditures within one year	<u>\$ 104,597</u>

As part of the Institute's liquidity management plan, cash in excess of daily requirements is invested in either money market funds, short-term investments or long-term investments. Investment decisions are based on anticipated liquidity needs, such that financial assets are available as general expenditures, liabilities, and other obligations come due. Additionally, the Institute maintains a \$10,000 line of credit, as discussed in Note 13.

8. FAIR VALUE MEASUREMENTS

FASB's guidance on the fair value option for financial assets and financial liabilities permits companies to choose to measure many financial assets and liabilities, and certain other items at fair value. This guidance requires a company to record unrealized gains and losses on items for which the fair value option has been elected in its performance indicator. The fair value option may be applied on an instrument by instrument basis. Once elected, the fair value option is irrevocable for that instrument. The fair value option can be applied only to entire instruments and not to portions thereof.

Kennedy Krieger Institute follows the guidance on fair value measurements, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, establishes a framework for measuring fair value, and expands disclosures about such fair value measurements. This guidance applies to other accounting pronouncements that require or permit fair value measurements and, accordingly, this guidance does not require any new fair value measurements.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

This guidance discusses valuation techniques such as the market approach, cost approach and income approach. The guidance establishes a three-tier level hierarchy for fair value measurements based upon the transparency of inputs used to value an asset of liability as of the measurement date. The three-tier hierarchy prioritizes the inputs used in measuring fair value as follows:

- Level 1 – Observable inputs such as quoted market prices for identical assets or liabilities in active markets;
- Level 2 – Observable inputs for similar assets or liabilities in an active market, or other than quoted prices in an active market that are observable either directly or indirectly; and
- Level 3 – Unobservable inputs in which there is little or no market data that requires the reporting entity to develop its own assumptions.

The financial instrument's categorization within the hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Each of the financial instruments below has been valued utilizing the market approach.

The following tables present the fair value of investments and liabilities as of June 30, 2019 and June 30, 2018, by the valuation hierarchy defined above and also presents information on the liquidity aspects of each investment.

Fair Value of Investments as of June 30, 2019				
	Level 1	Level 2	Level 3	Total Fair Value
Investments:				
Money market funds ⁽¹⁾	\$ 635	\$ -	\$ -	\$ 635
Fixed income mutual funds ⁽²⁾	19,119	-	-	19,119
Equity securities and funds ⁽³⁾	44,788	-	-	44,788
Alternative investments ⁽⁴⁾	-	-	-	-
Total Investments	<u>\$ 64,542</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 64,542</u>
Liabilities:				
Interest rate swap	<u>\$ -</u>	<u>\$ 8,359</u>	<u>\$ -</u>	<u>\$ 8,359</u>
Total Liabilities	<u>\$ -</u>	<u>\$ 8,359</u>	<u>\$ -</u>	<u>\$ 8,359</u>

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

	Fair Value of Investments as of June 30, 2018			
	Level 1	Level 2	Level 3	Total Fair Value
Investments:				
Money market funds ⁽¹⁾	\$ 7,701	\$ -	\$ -	\$ 7,701
Fixed income mutual funds ⁽²⁾	18,328	-	-	18,328
Equity securities and funds ⁽³⁾	44,524	-	-	44,524
Alternative investments ⁽⁴⁾	-	-	803	803
Total Investments	<u>\$ 70,553</u>	<u>\$ -</u>	<u>\$ 803</u>	<u>\$ 71,356</u>
Liabilities:				
Interest rate swap	<u>\$ -</u>	<u>\$ 6,320</u>	<u>\$ -</u>	<u>\$ 6,320</u>
Total Liabilities	<u>\$ -</u>	<u>\$ 6,320</u>	<u>\$ -</u>	<u>\$ 6,320</u>

- (1) Money market funds include investments in short-term debt securities, including US Treasury bills and commercial paper with same day or next day liquidity.
- (2) Fixed income mutual funds include funds whose underlying investments include domestic and international corporate bonds, obligations issued or guaranteed by the U.S. government or its agencies, bankers acceptances, bank certificates of deposit, repurchase agreements, commercial paper, fixed income instruments denominated in currencies of emerging market countries and fixed income instruments represented by forwards or derivatives including options, future contracts and swap agreements. All funds offer next day liquidity. All funds are traded in active markets.
- (3) Equity funds include investments in common stock mutual funds with next day liquidity.
- (4) Alternative investments include investments in a pooled investment fund of funds with underlying investments in equity long and short positions, distressed credit and private investments. Distributions from the fund have been limited by the fund of funds manager. As of June 30, 2019, all funds have been distributed. In addition, privately held common stock of a privately held company is included. There is currently no market for the common stock.

The Institute has also classified the valuation of its interest rate swap in Level 2 of the fair value hierarchy. For over-the-counter derivatives that trade in liquid markets, such as interest rate swaps, model inputs (i.e. contractual terms, market prices, yield curves, credit curves, and measures of volatility) can generally be verified, and model selection does not involve significant management judgment.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

9. PROPERTY AND EQUIPMENT

A summary of property and equipment at June 30, 2019 and 2018 is as follows:

	2019	2018
Land	\$ 4,657	\$ 4,657
Building and improvements	213,359	168,335
Furniture & equipment	44,976	44,960
	<u>262,992</u>	<u>217,952</u>
Less: Accumulated depreciation	(108,818)	(106,695)
	<u>154,174</u>	<u>111,257</u>
Construction in progress	7,653	33,977
Property and equipment, net	<u>\$ 161,827</u>	<u>\$ 145,234</u>

Depreciation expense was \$9,917 and \$9,159 in 2019 and 2018, respectively.

Construction of the 1741 Ashland Avenue building was completed in December 2018 at a cost of \$46,000. The 8-story, 130,000 square foot building houses clinical programs and support services. The construction of the building was financed through the Series 2017A Bonds as further described in Note 13, along with state and private support. Interest incurred during the construction is being capitalized as part of the project costs and totaled \$537 and \$771 in 2019 and 2018, respectively.

Capital Lease Obligations

The Institute entered into a lease agreement for computer equipment, software and the renovation of leased space. The Institute recorded these leases as capital leases and capitalized the property and equipment on the Consolidated Balance Sheets.

The future minimum lease payments required under the capital lease are as follows:

2020	\$ 972
2021	649
2022	653
2023	483
2024	<u>130</u>
Total future minimum lease payments	<u>\$ 2,887</u>

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

10. PLEDGES RECEIVABLE

Pledges receivable at June 30, 2019 and 2018 are summarized below:

	2019	2018
Pledges receivable:		
With donor restrictions	\$ 5,047	\$ 13,327
Without donor restrictions	<u>1,544</u>	<u>1,682</u>
Total pledges receivable	6,591	15,009
Less: Present value adjustment	(304)	(644)
Allowance for uncollectible pledges	<u>(1,930)</u>	<u>(1,564)</u>
Net pledges receivable	4,357	12,801
Less: Pledges due within one year	<u>(2,656)</u>	<u>(9,038)</u>
Pledges due in one to five years	<u>\$ 1,701</u>	<u>\$ 3,763</u>

The present value adjustments for 2019 and 2018 were made utilizing discount rates in effects at the time of the gift. The allowance for uncollectible pledges has been estimated based on management evaluation of each pledge's likelihood to be collected and using historical pledge write-off rates.

11. SIGNIFICANT CONCENTRATIONS OF CREDIT RISK

Financial instruments which potentially subject the Institute to concentrations of credit risk consist primarily of cash and cash equivalents, investments and patient accounts receivable.

The Institute typically maintains cash and cash equivalents in commercial banks. The short-term investments consist primarily of money market funds. The Federal Deposit Insurance Corporation insures funds up to \$250,000 per depositor.

The fair value of the Institute's investments are subject to various market fluctuations which include changes in the interest rate environment and general economic conditions.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

The Institute records patient receivables due for services provided to patients and others. The majority of these patients either qualify for federal/state assistance programs or have insurance through commercial insurance companies or managed care organizations. The Institute maintains reserves for potential losses and such losses have been within management's expectations. The mix of patient receivables due from patients and third-party payors at June 30, 2019 and 2018 areas follows:

	2019	2018
Medicaid	13.4 %	10.0 %
Medicaid Managed Care Organizations	11.1 %	12.3 %
Total Medicaid	<u>24.5 %</u>	<u>22.3 %</u>
Commercial Insurance	30.4 %	39.2 %
Blue Cross	23.9 %	19.3 %
Commercial Managed Care	12.2 %	11.7 %
Self-pay and other	7.2 %	5.7 %
Medicare	1.8 %	1.8 %
	<u>100.0 %</u>	<u>100.0 %</u>

12. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses at June 30, 2019 and 2018 are made up of the following:

	2019	2018
Accounts payable and other accrued expenses	\$ 14,326	\$ 14,978
Payroll	8,918	8,229
Vacation	5,675	5,322
Workers' compensation, unemployment and health benefits	3,414	2,756
Self-insurance - general/professional liability	1,617	1,594
Research subcontracts	1,793	1,228
	<u>\$ 35,743</u>	<u>\$ 34,107</u>

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

13. DEBT

Tax-exempt Bonds

Tax-exempt bonds issued through Maryland Health and Higher Educational Facilities Authority("MHHEFA") at June 30, 2019 and 2018 consisted of the following:

	2019	2018
MHHEFA Series 2011 Bonds	\$ 15,417	\$ 16,543
MHHEFA Series 2012 Bonds	400	1,599
MHHEFA Series 2013 Bonds	16,070	16,085
MHHEFA Series 2017A Bonds	22,734	23,000
MHHEFA Series 2017B Bonds	26,413	26,931
	<u>81,034</u>	<u>84,158</u>
Less: Current portion	(3,204)	(3,125)
Less: Unamortized deferred financing costs	(583)	(630)
	<u>\$ 77,247</u>	<u>\$ 80,403</u>

The Series 2011 Bonds are privately placed with Bank of America through a \$19,610 non-bank qualified term loan with a maturity date of June 1, 2021. The loan is being amortized through July 1, 2036. Terms of the loan agreement call for interest to be paid based on a percentage of 30-day LIBOR plus a bank spread. Principal payments are due in monthly installments on the firstday of each month.

The Series 2012 Bonds were privately placed in October 2012 with BB&T through a \$7,880 non-bank qualified term loan with a maturity date of July 1, 2019. The loan is also being amortized through the same period. Principal and interest are due in monthly installments on the first day of each month. Terms of the loan agreement call for a fixed interest rate of 2.76%.

The Series 2013 Bonds issued through MHHEFA were privately placed with Bank of America through a \$16,730 non-bank qualified term loan with a maturity date of July 1, 2023. The loan is being amortized through July 1, 2033. Principal and interest are due in monthly installments on the first day of each month. Terms of the loan call for a fixed interest rate of 3.62%.

The Series 2017A Bonds issued through MHHEFA were privately placed in March 2017 with Capital One Municipal Funding through a \$23,000 non-bank qualified term loan with a maturity date of April 1, 2027. The loan is being amortized through March 1, 2042. Principal and interest payments are due in monthly installments on the first day of each month. Principal payments began on April 1, 2019. Terms of the loan agreement called for a fixed rate of interest of 3.21%. Due to the change in the maximum federal corporate tax rate, the loan agreement was amended in May 2018, for a fixed rate of interest of 3.79%.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

The Series 2017B Bonds issued through MHHEFA were privately placed with BB&T through a \$27,510 non-bank qualified term loan with a maturity date of April 1, 2027. The loan is being amortized through March 1, 2037. Terms of the loan agreement call for interest to be paid based on a percentage of 30-day LIBOR plus a bank spread. Principal and interest payments are due in monthly installments on the first day of each month.

The obligated group for the Series 2011, 2012, 2013 and 2017A and B Bonds (the "Bonds") include Kennedy Krieger Institute, Inc. and each of its affiliated entities. The Bonds were issued in parity and contain certain restrictions on the Institute's ability to incur additional indebtedness, restrict its use of facilities, maintain stipulated insurance coverage and maintain a rate structure sufficient to meet its total annual cash requirements. The Institute must maintain compliance with certain debt covenants contained in the bond indentures and loan agreements. At June 30, 2019 and 2018, the Institute was in compliance with all debt covenants in accordance with these agreements.

The aggregate future maturities of bonds payable for the next five years and thereafter are summarized below at June 30, 2019.

2020	\$	3,204
2021		3,292
2022		3,384
2023		3,471
2024		3,550
Thereafter		64,133
	\$	<u>81,034</u>

Unamortized deferred bond financing costs of \$583 in 2019 and \$630 in 2018 are netted against tax-exempt bonds. Amortization expense was \$48 and \$55 in 2019 and 2018, respectively.

Line of Credit

The Institute maintains a working capital line of credit with a bank. The committed amount under the line of credit is \$10,000 through June 30, 2019 and increases to \$20,000 effective July 1, 2019 through December 31, 2019. The balance on the line of credit was \$1,000 at June 30, 2019. The line of credit is secured by a pledge on the revenues of the Institute and the debt covenant requirements are consistent with those of the Series 2011 and 2013 Bonds held by the bank.

14. RETIREMENT PLANS

The Institute maintains defined benefit and defined contribution plans covering substantially all of its employees.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

Defined Benefit Plan

The Institute's defined benefit pension plan (the "plan") provides benefits to staff-level employees based on years of service and the employees' final average compensation. The Institute's policy is to annually fund the amount necessary to meet minimum funding requirement under ERISA. Contributions of \$2,756 and \$2,111 were made for 2019 and 2018, respectively. The plan was amended effective April 1, 2019 to allow lump sum payments to employees hired before July 1, 1989 and to allow in-service distributions to Plan participants who reach normal retirement age while still employed. The settlement amount for these lump sum payments was \$4,947.

The net periodic benefit cost calculated in accordance with current guidance for employer's accounting for pension obligations is \$3,845 and \$2,381 for 2019 and 2018, respectively.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

The following table sets for the plan's funded status and benefit obligations recognized in the Institute's financial statements at June 30, 2019 and 2018:

	2019	2018
Change in benefit obligation:		
Projected benefit obligation at beginning of year	\$ 54,872	\$ 56,695
Service cost	771	615
Interest cost	2,335	2,274
Actuarial loss (gain)	6,512	(2,242)
Benefits paid	(782)	(2,470)
Settlements paid	(4,947)	-
Projected benefit obligation at end of year	<u>58,761</u>	<u>54,872</u>
Change in plan assets:		
Fair value of plan assets at beginning of year	40,132	38,502
Actual return on plan assets	2,647	1,989
Employer contribution	2,756	2,111
Benefits paid	(782)	(2,470)
Settlements paid	(4,947)	-
Fair value of plan assets at end of year	<u>39,806</u>	<u>40,132</u>
Funded status at end of year		
Recognized in noncurrent liabilities	<u>\$ (18,955)</u>	<u>\$ (14,740)</u>
Amounts not yet recognized in net periodic benefit cost and included in unrestricted net assets:		
Accumulated actuarial loss	\$ (20,063)	\$ (16,937)
Net unrestricted net assets previously reflected	<u>1,108</u>	<u>2,197</u>
Net amount recognized	<u>\$ (18,955)</u>	<u>\$ (14,740)</u>
Components of net periodic pension cost:		
Service cost	\$ 771	\$ 615
Interest cost	2,335	2,274
Expected return on plan assets	(2,383)	(2,382)
Loss on amortization	1,431	1,874
Effect of settlement	1,691	-
Net periodic pension cost	<u>3,845</u>	<u>2,381</u>
Changes in net assets not yet reflected in the statement of operations:		
Unrecognized net loss (gain)	6,288	(1,849)
Amortization of unrecognized net loss	<u>(3,122)</u>	<u>(1,874)</u>
Total changes in plan assets and obligations not yet reflected	<u>3,166</u>	<u>(3,723)</u>
Total changes in plan assets and benefit obligations	<u>\$ 7,011</u>	<u>\$ (1,342)</u>
Unrecognized net loss to be amortized over next fiscal year	<u>\$ (1,975)</u>	<u>\$ (1,432)</u>

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

	2019	2018
Additional information:		
Accumulated benefit obligation	\$ 58,761	\$ 54,872
Expected contributions in the following year	\$ 3,315	\$ 2,775

Expected benefit payments for fiscal year ending June 30, 2018:

2020	\$ 1,718
2021	1,937
2022	2,113
2023	2,247
2024	2,291
Next five years	13,086

**Weighted-average assumptions
to determine benefit obligations:**

	2019	2018
Discount rate	3.55%	4.33%
Salary increase	Non applicable	Non applicable
Measurement date	30-Jun	30-Jun
Participant census data used	January 1, 2019	January 1, 2018

**Weighted-average assumptions
to determine pension expense:**

	2019	2018
Discount rates	4.33%	4.07%
Expected return on plan assets	6.00%	6.25%
Salary increase	Non applicable	Non applicable

The discounted rate assumption for fiscal year ending 2019 was based on the FTSE Pension Above-Median Discount Curve as of June 30, 2019. The fiscal year 2018 discounted rate assumption was determined using the prior actuary's proprietary yield curve, under which the plan's projected benefit payments are matched against a series of spot rates derived from a market basket of high quality fixed income securities. The mortality tables used in fiscal year 2019 are based on the RP-2014 mortality table, no collar adjustment, and the MP-2018 mortality projection scale. The mortality tables used in fiscal 2018 by the prior actuary were based on the adjusted RP-2014 tables, no collar adjustment, and an adjusted MP-2016 mortality improvement scale.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

In determining the expected long-term rate of return on plan assets, the Institute evaluated the historical long-term rate of return for each class of asset in determining an acceptable overall range of expected returns for the plan.

The following tables present fair value measurements for plan assets as of June 30, 2019 and 2018 by the valuation hierarchy as defined in footnote 8 and also includes the liquidity aspects of each investment:

Fair Value of Investments as of June 30, 2019				
	Level 1	Level 2	Level 3	Total Fair Value
Investments:				
Money market funds ⁽¹⁾	\$ 191	\$ -	\$ -	\$ 191
Fixed income mutual funds ⁽²⁾	13,838	-	-	13,838
Equity securities and funds ⁽³⁾	25,777	-	-	25,777
Alternative investments ⁽⁴⁾	-	-	-	-
Total Investments	<u>\$ 39,806</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 39,806</u>

Fair Value of Investments as of June 30, 2018				
	Level 1	Level 2	Level 3	Total Fair Value
Investments:				
Money market funds ⁽¹⁾	\$ 218	\$ -	\$ -	\$ 218
Fixed income mutual funds ⁽²⁾	13,885	-	-	13,885
Equity securities and funds ⁽³⁾	25,829	-	-	25,829
Alternative investments ⁽⁴⁾	-	-	200	200
Total Investments	<u>\$ 39,932</u>	<u>\$ -</u>	<u>\$ 200</u>	<u>\$ 40,132</u>

- (1) Money market funds include investments in short-term debt securities, including US Treasury bills and commercial paper with same day or next day liquidity.
- (2) Fixed income mutual funds include funds whose underlying investments include domestic and international corporate bonds, obligations issued or guaranteed by the U.S. government or its agencies, bankers acceptances, bank certificates of deposit, repurchase agreements, commercial paper, fixed income instruments denominated in currencies of emerging market countries and fixed income instruments represented by forwards or derivatives including options, future contracts and swap agreements. All funds offer next day liquidity. All funds are traded in active markets.
- (3) Equity funds include investments in common stock mutual funds with next day or monthly liquidity.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

- (4) Alternative investments include investments in a pooled investment fund of funds with underlying investments in equity long and short positions, distressed credit and private investments. Distributions from the fund have been limited by the fund of funds manager. In addition, privately held common stock of a privately held company is included. There is currently no market for the common stock. All funds have been distributed as of June 30, 2019 and the balance at June 30, 2019 is \$0.

The plan's target allocations and actual asset allocation at June 30, by asset category, was as follows:

	Target Allocation	Actual Allocation	
		2019	2018
Money market funds	-	-	0.5 %
Equities	65 %	64.7 %	64.4 %
Fixed income	35 %	34.8 %	34.6 %
Absolute return funds	-	-	0.5 %
	<u>100</u>	<u>99.5</u>	<u>100</u>

The objectives of the plan's investment strategy are to maximize the plan's funded status and minimize the Institute's contributions and plan expense.

The Investment Committee establishes a target asset allocation and regularly reviews the actual asset allocation against the target. It also periodically rebalances the investment allocations, as appropriate.

Defined Contribution Plan

The Institute maintains a qualified defined contribution retirement plan which is in compliance with section 401(k) of the Internal Revenue Code (IRC). The 401(k) plan is active and available to all employees (including all faculty and senior staff members) and provides for up to a 50% employer match on employee contributions up to certain levels of compensation. During 2019 and 2018, the aggregate contributions to the 401(k) plan were \$20,085 and \$18,025.

Deferred Compensation Plan

The Institute also offers a non-qualified deferred compensation plan (457(b) of the IRC) for certain of its executives which allows for the deferral of compensation up to IRS limits. A deferred compensation balance of \$2,104 and \$1,949 in fiscal years 2019 and 2018, respectively, was reported in Investments limited as to use in the Consolidated Balance Sheet. An associated liability of an equal amount is included in Other long-term liabilities in the Consolidated Balance Sheet. The Institute makes no contributions to the Deferred Compensation Plan.

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

15. INTEREST RATE SWAP

The Institute manages the fixed/variable mix of its debt portfolio, including hedging exposure to increasing interest expense on variable rate debt, by utilizing an interest rate swap. The Institute maintains a fixed payor interest rate swap which hedges the variable interest rate risk on the majority of the outstanding balance of the Series 2017B and 2011 Series Bonds. Under the terms of the agreement with a local bank, the Institute pays a fixed rate of 3.636% and receives 67% of 30-day LIBOR on notional amounts that reduce annually until July 2036. Notional amounts of \$36,064 and \$36,659 were effective June 30, 2019 and 2018, respectively. Under the terms of the agreement, no collateral requirements exist on the part of the Institute.

The fair value of the interest rate swap and the related unrealized (losses) were as follows as of June 30, including the classification on the Consolidated Balance Sheets and Statements of Operations:

	Fair Market Value	
	2019	2018
Interest rate swap liability	\$ 8,359	\$ 6,320
	Amount recognized in Non-operating activity	
	2019	2018
Unrealized gain (loss) on interest rate swap valuation	\$ (2,039)	\$ 2,226
Interest rate swap payments	(739)	(955)
Total	<u>\$ (2,778)</u>	<u>\$ 1,271</u>

16. NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions were held for the following purposes at June 30, 2019 and 2018:

	2019	2018
Capital Campaigns	\$ 3,989	\$ 15,684
Research and clinical projects	19,082	18,920
Perpetual in nature	1,229	1,220
	<u>\$ 24,300</u>	<u>\$ 35,824</u>

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

During 2019 and 2018, net assets with donor restrictions were released by satisfying donor restrictions in the following amounts:

	2019	2018
Property and equipment	\$ 10,340	\$ 5,005
Operating activities	<u>6,441</u>	<u>3,819</u>
Total	<u>\$ 16,781</u>	<u>\$ 8,824</u>

17. SELF INSURANCE

Professional and General Liability

The Institute maintains a self-insurance trust (the "Trust") for general and professional liability to cover liability claims arising out of the ordinary course of its business. Excess coverage with an insurance company is in place to cover losses above self-insured retention levels.

Assets in the Trust are to provide for payment of professional and general liability claims and expenses. Potential losses from asserted and unasserted claims are accrued based on estimates that incorporate the Institute's past experience, as well as other considerations, including the nature of each claim or incident, applicable insurance coverage and relevant trend factors.

An accrued liability related to asserted and unasserted self-insured general and professional liability claims of \$1,617 and \$1,594 has been recorded at June 30, 2019 and 2018, respectively, and is included in Accounts payable and accrued expenses on the Consolidated Balance Sheets. Investments in the Trust have a market value of \$4,486 and \$4,212 at June 30, 2019 and 2018, respectively and are reported in Investments limited as to use on the Consolidated Balance Sheets.

Workers' Compensation, Unemployment and Health Benefits

The Institute self-insures its workers' compensation, unemployment and employee health and dental benefits. Losses from claims identified by the Institute, as well as provisions for estimated losses for incurred but not reported incidents, are accrued based on estimates that incorporate the past experience of the Institute, as well as other considerations, including the nature of the claims or incidents and relevant trend factors. An accrued liability of \$3,414 and \$2,756 has been recorded at June 30, 2019 and 2018, respectively for these self-insured plans and is included in Accounts payable and accrued expenses on the Consolidated Balance Sheets.

18. COMMITMENTS AND CONTINGENCIES

Litigation

The Institute is involved in claims and litigation on professional liability and personnel matters that arise in the ordinary course of its business. This litigation is not expected to

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

result in losses that exceed insurance limits or have a materially adverse effect on the Institute's financial position.

There have been claims filed against the Hugo W. Moser Research Institute at Kennedy Krieger, Inc. arising out of two Federally-funded research studies performed in the early 1990s. The Institute has insurance believed adequate to cover any compensatory damages awarded for these claims. The Institute has been successful in defending its position on these cases and do not anticipate any material exposure going forward.

Rental Lease Commitments

Through the creation of MSP, all property and major equipment is leased/subleased to each operating entity. These transactions are eliminated through the consolidating of the Institute's financial statements.

Commitments for leases that do not meet the criteria for capitalization are classified as operating leases with related rentals charged to operations as incurred. The following is a schedule by year of future minimum lease payments under operating leases as of June 30, 2019, that have initial or remaining lease terms in excess of one year.

2020	\$	2,698
2021		2,253
2022		2,177
2023		1,259
2024		230
Thereafter		1,178
	\$	<u>9,795</u>

Rent expense on external lease commitments for the years ended June 30, 2019 and 2018 was \$2,572 and \$2,800, respectively.

Charitable Gift Annuities

The Institute has received charitable gift annuities from donors from which the Institute has guaranteed payments to the donor on a quarterly basis until the donor's death.

The Institute has recorded gift annuities, net of reserves, consistent with the rates adopted by the American Council on Gift Annuities at the time of issuance of the gift annuity. Assets maintained on outstanding annuity agreements exceed the amount of the reserve. Gift annuities with a market value of \$707 and \$689 and reserves for annuity payments of \$422 and \$423 to make gift annuity payments have been recorded in 2019 and 2018, respectively, and are included in Investments limited as to use on the Consolidated Balance Sheets.

Epic Outpatient Clinical System

The Institute entered into agreements with Epic to license and implement a new clinical system for use in outpatient services. As part of the agreements, the Institute committed

See accompanying notes to consolidated financial statements.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2019 and 2018
(in thousands)

to a 4-year payment plan which included both the license fees and implementation costs. Through the end of fiscal year 2019, \$2,988 has been paid under this commitment. The future year commitments are as follows:

2020	\$	1,992
2021		1,992
2022		1,013
	\$	<u>4,997</u>

19. FUNCTIONAL EXPENSES

The Institute provides specialty pediatric health care services, conducts laboratory and clinical research, operates special education school programs and administers community-based services, conducts fundraising activities and provides institutional support. Costs not directly attributable to a function, including depreciation and interest, are allocated to function based on square footage. Expenses related to providing these services are as follows:

June 30, 2019						
	Healthcare	Research	Education/ Community Svcs	Fundraising	Institutional Support	Total
Salaries, wages and benefits	\$ 122,028	\$ 14,888	\$ 39,309	\$ 2,064	\$ 25,113	\$ 203,402
Supplies and other	19,523	9,593	4,238	1,495	15,302	50,151
Rent	1,888	-	452	-	232	2,572
Interest	1,196	243	696	12	383	2,530
Depreciation	4,712	956	2,740	50	1,507	9,965
Total	<u>\$ 149,347</u>	<u>\$ 25,680</u>	<u>\$ 47,435</u>	<u>\$ 3,621</u>	<u>\$ 42,537</u>	<u>\$ 268,620</u>

June 30, 2018						
	Healthcare	Research	Education/ Community Svcs	Fundraising	Institutional Support	Total
Salaries, wages and benefits	\$ 112,276	\$ 15,133	\$ 39,563	\$ 2,240	\$ 23,332	\$ 192,544
Supplies and other	17,818	8,363	4,053	1,622	18,277	50,133
Rent	1,844	-	439	-	517	2,800
Interest	883	226	546	11	216	1,882
Depreciation	4,321	1,109	2,672	55	1,057	9,214
Total	<u>\$ 137,142</u>	<u>\$ 24,831</u>	<u>\$ 47,273</u>	<u>\$ 3,928</u>	<u>\$ 43,399</u>	<u>\$ 256,573</u>

20. SUBSEQUENT EVENTS

The Institute has evaluated subsequent events through September 25, 2019, which is the date the Consolidated Financial Statements were issued. There have been no events subsequent to that date that needed to be disclosed.

See accompanying notes to consolidated financial statements.



Report of Independent Auditors

To the Board of Directors of Kennedy Krieger Institute, Inc. and Affiliates We have audited the consolidated financial statements of Kennedy Krieger Institute, Inc. and Affiliates, as of June 30, 2019 and for the year then ended and our report thereon appears on pages 1 of this document. That audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The consolidating information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the consolidating information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, results of operations, changes in net assets and cash flows of the individual companies and is not a required part of the consolidated financial statements. Accordingly, we do not express an opinion on the financial position, results of operations, changes in net assets and cash flows of the individual companies.

PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP
Baltimore, Maryland
September 25, 2019

SUPPLEMENTAL CONSOLIDATING FINANCIAL STATEMENTS

Kennedy Krieger Institute, Inc. and Affiliates
Consolidating Balance Sheet
June 30, 2019

	Kennedy Krieger Children's Hospital, Inc.	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	Kennedy Krieger Education & Community Services, Inc.	Kennedy Krieger Foundation, Inc.	PACT: Helping Children With Special Needs, Inc.	Madison Street Properties, Inc.	Consolidating Eliminations	Consolidated Totals
Assets								
Current Assets:								
Cash and cash equivalents	\$ 1,728,442	\$ -	\$ -	\$ 7,030,331	\$ 290,956	\$ -	\$ -	\$ 9,049,729
Patient receivable, net	22,978,744	-	1,625,419	-	137,585	-	-	24,741,748
Grant and contract receivable	157,367	3,187,923	1,095,268	-	384,772	-	-	4,825,330
Tuition receivable	-	-	4,201,407	-	-	-	-	4,201,407
Pledges receivable	-	-	-	2,656,370	-	-	-	2,656,370
Due from affiliates	58,548,912	-	7,547,834	4,345,628	197,057	-	(70,639,431)	-
Investments limited as to use	-	-	-	-	-	-	-	-
Prepaid expenses and other	1,733,324	616,888	185,000	3,798	1,697	190,574	(185,000)	2,546,281
Total Current Assets	85,146,789	3,804,811	14,654,928	14,036,127	1,012,067	190,574	(70,824,431)	48,020,865
Non-current Assets:								
Property and equipment, net	-	-	-	-	-	161,826,770	-	161,826,770
Long-term investments	-	-	-	56,202,800	373,464	-	-	56,576,264
Investments limited as to use	6,589,734	-	-	1,671,389	-	-	-	8,261,123
Pledges receivable, net	-	-	-	1,700,759	-	-	-	1,700,759
Total Non-Current Assets	6,589,734	-	-	59,574,948	373,464	161,826,770	-	228,364,916
Total Assets	\$ 91,736,523	\$ 3,804,811	\$ 14,654,928	\$ 73,611,075	\$ 1,385,531	\$ 162,017,344	\$ (70,824,431)	\$ 276,385,781
Liabilities and Net Assets								
Current Liabilities:								
Accounts payable and accrued expenses	\$ 30,782,766	\$ 1,794,878	\$ 147,698	\$ 151,000	\$ 66,654	\$ 2,798,935	\$ -	\$ 35,741,931
Deferred grant revenue	5,650	1,365,143	239,506	-	127,813	-	-	1,738,112
Line of credit	1,000,000	-	-	-	-	-	-	1,000,000
Due to affiliates	-	14,703,664	-	-	-	55,935,767	(70,693,431)	(54,000)
Current portion of tax-exempt bonds	-	-	-	-	-	3,204,035	-	3,204,035
Total Current Liabilities	31,788,416	17,863,685	387,204	151,000	194,467	61,938,737	(70,693,431)	41,630,078
Non-current Liabilities:								
Tax-exempt bonds, net	-	-	-	-	-	77,247,184	-	77,247,184
Accrued pension	18,955,015	-	-	-	-	-	-	18,955,015
Interest rate swap	-	-	-	-	-	8,358,738	-	8,358,738
Other long-term liabilities	4,250,137	-	-	-	-	-	-	4,250,137
Total Long-Term Liabilities	23,205,152	-	-	-	-	85,605,922	-	108,811,074
Total Liabilities	54,993,568	17,863,685	387,204	151,000	194,467	147,544,659	(70,693,431)	150,441,152
Net Assets:								
Without donor restrictions	33,327,480	(18,885,316)	13,045,006	59,397,149	418,427	14,472,685	(185,000)	101,590,431
With donor restrictions	3,415,475	4,826,442	1,222,718	14,062,926	772,637	-	-	24,300,198
Total Net Assets	36,742,955	(14,058,874)	14,267,724	73,460,075	1,191,064	14,472,685	(185,000)	125,890,629
Total Liabilities and Net Assets	\$ 91,736,523	\$ 3,804,811	\$ 14,654,928	\$ 73,611,075	\$ 1,385,531	\$ 162,017,344	\$ (70,878,431)	\$ 276,331,781

Kennedy Krieger Institute, Inc. and Affiliates

Consolidating Statement of Operations and Changes in Net Assets

Year Ended June 30, 2019

	Kennedy Krieger Hospital, Inc	Hugo W. Moser Research Inst at Kennedy Krieger, Inc.	Kennedy Krieger Education & Community Services, Inc.	Kennedy Krieger Foundation Inc.	PACT: Helping Children with Special Needs, Inc.	Madison Street Properties Inc.	Consolidating Eliminations	Consolidated Totals
Operating revenues:								
Patient service revenue, net	\$ 167,875,223	\$ 2,875,775	\$ 2,367,830	\$ -	\$ 227,803	\$ -	\$ -	\$ 173,346,631
Tuition revenue	62,337	-	47,052,288	-	638,773	-	-	47,753,398
Grant and contract revenue	2,224,538	26,311,769	4,547,825	-	1,925,717	-	-	35,009,849
Net assets released for operating activities	1,178,879	2,166,623	1,140,744	12,184,119	110,538	1,316,868	(11,656,798)	6,440,973
Investment earnings used for operating activities	-	-	-	2,040,000	-	-	-	2,040,000
Contributions from fundraising activities, net	-	-	-	1,550,692	-	-	-	1,550,692
Other operating revenues	861,448	3,344,338	3,948	(2,040,000)	361,207	33,518,769	(34,888,812)	1,160,898
Total operating revenues	172,202,425	34,698,505	55,112,635	13,734,811	3,264,038	34,835,637	(46,545,610)	267,302,441
Operating expenses:								
Salaries, wages and benefits	129,014,836	19,643,411	42,323,490	987,198	2,743,737	7,514,239	-	202,226,911
Supplies, purchased services and other	22,186,057	10,499,119	6,018,282	12,443,566	417,941	11,794,125	(13,884,888)	49,474,202
Space costs, net	19,534,689	5,742,650	6,558,754	252,344	111,778	460,507	(32,660,722)	-
Depreciation	-	-	-	-	-	9,965,136	-	9,965,136
Rent	-	-	-	-	-	2,572,066	-	2,572,066
Interest	-	-	-	-	-	2,529,564	-	2,529,564
Total operating expenses	170,735,582	35,885,180	54,900,526	13,683,108	3,273,456	34,835,637	(46,545,610)	266,767,879
Operating revenues over (under) expenses	1,466,843	(1,186,675)	212,109	51,703	(9,418)	-	-	534,562
Non-operating activity:								
Investment return, net	274,293	-	-	783,447	18,438	2,801	-	1,078,979
Gain (loss) on interest rate swap	-	-	-	-	-	(2,778,309)	-	(2,778,309)
Restricted fundraising expenses	-	-	-	(1,167,369)	-	-	-	(1,167,369)
Net non-operating activities	274,293	-	-	(383,922)	18,438	(2,775,508)	-	(2,866,699)
Excess of revenues (under) over expenses	\$ 1,741,136	\$ (1,186,675)	\$ 212,109	\$ (332,219)	\$ 9,020	\$ (2,775,508)	\$ -	\$ (2,332,137)
Net assets w ithout donor restrictions:								
Excess of revenue over (under) operating expenses	\$ 1,741,136	\$ (1,186,675)	\$ 212,109	\$ (332,219)	\$ 9,020	\$ (2,775,508)	\$ -	\$ (2,332,137)
Net assets released from restrictions for property and equipment	-	-	-	-	-	10,339,930	-	10,339,930
Change in funded status of defined benefit plan	(6,200,277)	-	-	-	-	-	-	(6,200,277)
Increase (decrease) in net assets w ithout donor restriction	(4,459,141)	(1,186,675)	212,109	(332,219)	9,020	7,564,422	-	1,807,516
Net assets w ithout donor restrictions, beginning of year	37,786,621	(15,698,641)	12,832,897	57,729,366	409,408	6,908,264	(185,000)	99,782,915
Net assets w ithout donor restrictions, end of year	33,327,480	(16,885,316)	13,045,006	57,397,147	418,428	14,472,686	(185,000)	101,590,431
Net assets w ith donor restrictions:								
Contributions from fundraising activities	1,048,495	(564,690)	1,619,018	2,913,693	240,170	-	-	5,256,686
Net assets released from restrictions used for:								
Operating activities	(1,175,880)	(2,112,231)	(1,140,744)	(1,901,783)	(110,538)	-	-	(6,441,176)
Purchases of property and equipment	(3,000)	(54,393)	-	(10,282,336)	-	-	-	(10,339,729)
Increase (decrease) in restricted net assets	(130,385)	(2,731,314)	478,274	(9,270,426)	129,632	-	-	(11,524,219)
Net assets w ith donor restrictions, beginning of year	3,545,860	5,557,756	744,444	25,333,354	643,003	-	-	35,824,417
Net assets w ith donor restrictions, end of year	3,415,475	2,826,442	1,222,718	16,062,928	772,635	-	-	24,300,198
Increase (decrease) in total net assets	(4,589,526)	(3,917,989)	690,383	(9,602,645)	138,652	7,564,422	-	(9,716,703)
Total net assets, beginning of year	41,332,481	(10,140,885)	13,577,341	83,062,720	1,052,411	6,908,264	(185,000)	135,607,332
Total net assets, end of year	\$ 36,742,955	\$ (14,058,874)	\$ 14,267,724	\$ 73,460,075	\$ 1,191,063	\$ 14,472,686	\$ (185,000)	\$ 125,890,629

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Supplemental Consolidating Financial Statements
for the year ended June 30, 2019

1. Basis of Presentation and Accounting

The consolidating supplemental schedules have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

The Supplemental Consolidating Financial Statements presented on pages 35-37 were derived from and relate directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial positions and changes in net assets of the individual companies within the Institute and are not a required part of the consolidated financial statements. The individual affiliates within the Institute as presented within the supplemental consolidating financial statements are disclosed within Note 1 to the consolidated financial statements.

**Schedule of Expenditures of Federal Awards
and
Notes to Schedule of Expenditures of Federal Awards**

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Pass Through Entity Identification Number		
Research and Development Cluster- Direct Awards					
Department of Health and Human Services					
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-01	186,318	
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-01	91,953	-
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-01	38,000	38,000
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-01	32,775	32,775
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-01	(626)	(626)
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-02	333,178	-
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-02	138,646	-
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-02	6,392	6,392
National Heart Lung, and Blood Institute					
MRI-based Quantitative Brain Perfusion Mapping for Sickle Cell Disease	R	93.839	K 25 HL121192-04	(49,235)	-
MRI-based Quantitative Brain Perfusion Mapping for Sickle Cell Disease	R	93.839	K 25 HL121192-05	81,616	11,534
Clinical and Neuroimagin Phenotypes of Neurological Disorders In Pediatric Sickle Cell Disease	R	93.839	K 23 HI133455-01A	32,964	-
Clinical and Neuroimagin Phenotypes of Neurological Disorders In Pediatric Sickle Cell Disease	R	93.839	K 23 HI133455-02A	147,112	-
MRI-based Quantitative Brain Oximetry for Sickle Cell Disease	R	93.839	K25 HL145129-01	15,244	-
Non-Contrast-Enhanced Velocity-Selective MR Angiography	R	93.837	R01HL138182-01	180,079	-
Non-Contrast-Enhanced Velocity-Selective MR Angiography	R	93.837	R01HL138182-02	252,255	-
National Institute of Biomedical Imaging and Bioengineering					
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-16 Miller sub	7,289	7,289
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-16 Caffo sub	45,258	45,258
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-17	6,335	-
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-17 Miller sub	135,010	103,570
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-17 Caffo sub	64,000	95,439
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-18	1,121,817	-
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-18 Suppl	180,740	126,699
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-18 Miller sub	126,699	88,538
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-18 Caffo sub	88,538	-
Resources for Quantitive Functional MRI	R	93.286	P41 RR15241-19	2,300	-
Novel Approaches for CEST Labeling, Detection, Quantification and Translation	R	93.286	5 R01 EB015032-06	1,371	-
Novel Approaches for CEST Labeling, Detection, Quantification and Translation	R	93.286	5 R01 EB015032-07	331,393	-
Development and Translation of D-Glucose as a Diagnostic Agent for MRI	R	93.286	R01EB019934-03	(16,427)	-
Development and Translation of D-Glucose as a Diagnostic Agent for MRI	R	93.286	R01EB019934-04	684,033	55,281

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title			Entity	Federal CFDA Number	Pass Through Entity Identification Number	
Development and Translation of D-Glucose as a Diagnostic Agent for MRI	R	93.286	R01EB019934-05		329,117	-
In Vivo Molecular MR Imaging of Inflammation Using NSAIDS as CEST Agents	R	93.286	R21EB020905-01		(28,061)	-
In Vivo Molecular MR Imaging of Inflammation Using NSAIDS as CEST Agents	R	93.286	R21EB020905-02		17,457	-
Presurgical Functional MRI in Patients w/ Large Susceptibility Artifacts	R	93.286	R21EB023538-01		(27,602)	-
Presurgical Functional MRI in Patients w/ Large Susceptibility Artifacts	R	93.286	R21EB023538-02		123,455	-
Role of Peripheral and Brain Iron in the Development of Attention	R	93.286	R03EB023359-01A1		71,904	-
Development and Translation of D-Glucose as an MRI Contrast Agent for MS	R	93.286	1K99EB026312-01A1		57,686	-
Development and Translation of D-Glucose as an MRI Contrast Agent for MS	R	93.286	1K99EB026312-02		23,795	-
Sensitivity Enhanced MRI Imaging of Receptor Binding in Breast Cancer	R	93.286	R21EB025295-01A1		145,196	-
Sensitivity Enhanced MRI Imaging of Receptor Binding in Breast Cancer	R	93.286	R21EB025295-02		27,621	-
National Institute of Child Health and Human Development						
Resident Training in Brain Injury Rehab	R	93.865	5T32HD007414-24		23,418	-
Resident Training in Brain Injury Rehab	R	93.865	5T32HD007414-25		98,462	-
Resident Training in Brain Injury Rehab	R	93.865	5T32HD007414-25		59,092	-
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865	R01 HD40289-15A		298,160	-
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865	R01 HD40289-15A JHU SUB		24,749	24,749
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865	R01 HD40289-16A		27,863	-
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-12		119,980	-
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-12 CELNIK SUB		7,826	7,826
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-12 KRAKA SUB		6,641	6,641
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-12 ZIPUNN SUB		7,884	7,884
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-13		391,956	-
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-13 CELNIK SUB		16,463	16,463
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-13 KRAKA SUB		16,343	16,343
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-13 ZIPUNN SUB		22,448	22,448
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-14		51,341	-
Development of ADHD in Preschool Children: Neuroimaging and Behavioral	R	93.865	R01 HD068425-05		17,618	-
Delineating Subtypes of Self-Injurious Behavior Maintained by Automatic	R	93.865	R01 HD076653-05		57,796	-
Delineating Subtypes of Self-Injurious Behavior Maintained by Automatic	R	93.865	R01 HD076653-06		8,768	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-03		262	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		948	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		73,352	73,352
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		5,888	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		16,531	(15,554)
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		331,981	19,773
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		266,020	96,725
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		161,251	29,648
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		144,853	-

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title			Entity	Federal CFDA Number	Pass Through Entity Identification Number	
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		71,168	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		142,401	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04		250,386	71,399
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06		15,810	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06		7,412	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06		5,578	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06		6,380	-
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06		1,934	-
Mechanisms Regulating KCC@ Hypofunction	R	93.865	R01 HD090884-01		53,333	-
Mechanisms Regulating KCC@ Hypofunction	R	93.865	R01 HD090884-02		363,602	27,432
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-01		366,339	-
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-01-CAFFO SUB		12,854	12,854
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-01- TEKES SUB		6,240	6,240
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-02		206,814	-
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-02-CAFFO SUB		6,818	6,818
National Institute of Mental Health						
Anomalous Motor Physiology in ADHD	R	93.242	R01 MH78160-10		(28,085)	-
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-11SA1		39,648	-
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-12A1		238,192	-
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-12A1 MILLER SUB		5,042	5,042
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-12A1 CAFFO SUB		2,068	2,068
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-12A1 GIEDD SUB		1,964	1,964
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-12A1 COHEN SUB		7,387	7,387
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1		506,624	-
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1-SUPP		132,558	107,445
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 MILLER SUB		39,827	39,827
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 CAFFO SUB		7,599	7,599
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 GIEDD SUB		5,246	5,246
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 COHEN SUB		2,645	2,645
Delay Discounting in children with ADHD: Neuroimaging	R	93.242	K23 MH101322-02		13,688	-
Delay Discounting in children with ADHD: Neuroimaging	R	93.242	K23 MH101322-03		50	-
Delay Discounting in children with ADHD: Neuroimaging	R	93.242	K23 MH101322-04		869	-
Delay Discounting in children with ADHD: Neuroimaging	R	93.242	K23 MH101322-05		62,636	-
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-01		320	-
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-03		23,317	2,908
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-04		272,968	1,394
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-04-SUPL		54,451	-
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-04-SCHARPF SUB		7,739	7,739
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-04-LANDMEAD SUB		13,518	13,518

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title			Federal CFDA Entity Number	Pass Through Entity Identification Number	
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-01-PHILIPS SUB	(35,572)	(35,572)
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-02	(12,210)	-
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-02-PHILIPS SUB	9,193	9,193
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-03	51,874	-
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-03 UWash Sub	47,785	7,626
Visual-Motor Development in Infants at High Risk for Autism	R	93.242	K01MH109766-01	305	-
Visual-Motor Development in Infants at High Risk for Autism	R	93.242	K01MH109766-02	3,620	-
Visual-Motor Development in Infants at High Risk for Autism	R	93.242	K01MH109766-03	101,027	-
Visual-Motor Development in Infants at High Risk for Autism	R	93.242	K01MH109766-04	21,144	-
Defining the Sluggish Cognitive Tempo Phenotype	R	93.242	R03 MH111965-01A	4,686	-
Defining the Sluggish Cognitive Tempo Phenotype	R	93.242	R03 MH111965-02A	66,051	-
A Novel Framework for Impaired Imitation in ASD	R	93.242	R01 MH113652-01A	182,528	-
A Novel Framework for Impaired Imitation in ASD	R	93.242	R01 MH113652-01-SUB	78,278	78,278
A Novel Framework for Impaired Imitation in ASD	R	93.242	R01 MH113652-02A	308,864	-
Behavioral and Neural Representations of Subjective Effort Cost	R	93.242	R56 MG113627-01A1	261,879	-
Behavioral and Neural Representations of Subjective Effort Cost	R	93.242	R56 MG113627-01A1	6,934	6,934
Genomic Basis of Pediatric Bipolar Disorder	R	93.242	R36 MH118005-01	23,436	-
National Institute of Neurological Disorders and Stroke					
Brain Cancer Stem Cells Reprog By C-Met	R	93.853	R01NS073611-D1A1	(1,991)	-
Magnetic Resonance Imaging and Apectroscopy	R	93.853	K23NS091379-02	44,851	-
Magnetic Resonance Imaging and Apectroscopy	R	93.853	K23NS091379-03	41,388	-
Magnetic Resonance Imaging and Apectroscopy	R	93.853	K23NS091379-04	88,480	-
Magnetic Resonance Imaging and Apectroscopy	R	93.853	K23NS091379-05	39,710	-
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-01	1,616	-
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-02	23,275	-
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-03	(19,949)	-
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-03 ZHU SUB	1,347	1,347
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-03 CHENG SUB	1,755	1,755
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-04	290,216	-
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-04 CHENG SUB	8,035	7,141
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-05	30,927	-
Direct Examination of Imitation-Based Learning in Autism	R	93-853	R21NS091569-02A1	(71)	-
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-01	8,654	-
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-02	56,897	-
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-02 CAFFO SUB	2,804	2,804
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-02 EDDEN SUB	4,373	4,373
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-02 CINN SUB	73,194	73,194
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-03	186,202	-
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-03	5,636	5,636

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title		Entity	Federal CFDA Number	Pass Through Entity Identification Number	
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-03	56,374	56,374
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-03	147,181	147,181
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-04	79,569	-
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-01	(27,165)	-
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-01	10,912	(16,253)
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-02	202	-
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-03	264,769	-
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-03	131,517	131,517
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-04	62,887	-
Child Neurologist Career Development Program	R	93-853	K12NS098482-01	18,838	-
Child Neurologist Career Development Program	R	93-853	K12NS098482-01 IOWA SUB	40,627	40,627
Child Neurologist Career Development Program	R	93-853	K12NS098482-01 BAYLOR SUB	64,635	64,635
Child Neurologist Career Development Program	R	93-853	K12NS098482-01 CH HOSP SUB	15,939	15,939
Child Neurologist Career Development Program	R	93-853	K12NS098482-01 JHU SUB	14,205	14,205
Child Neurologist Career Development Program	R	93-853	K12NS098482-01 UCAL SUB	144,764	144,764
Child Neurologist Career Development Program	R	93-853	K12NS098482-02	3,317	-
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 COLO SUB	4,144	4,144
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 CORNELL SUB	2,072	2,072
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 ROCHESTER SUB	1,367	1,367
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 IOWA SUB	142,907	142,907
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 UCAL SUB	47,991	47,991
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 SEATTLE SUB	68,567	68,567
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 DUKE SUB	123,142	123,142
Child Neurologist Career Development Program	R	93-853	K12NS098482-03	154,090	-
Child Neurologist Career Development Program	R	93-853	K12NS098482-03 CH HOSP SUB	100,240	100,240
Child Neurologist Career Development Program	R	93-853	K12NS098482-03-STANFORD SUB	127,939	127,939
Child Neurologist Career Development Program	R	93-853	K12NS098482-03-WASH SUB	69,596	69,596
Chromatin Modifications in GBM-Propagating Cells	R	93-853	R01NS096754-01A	66,168	-
Chromatin Modifications in GBM-Propagating Cells	R	93-853	R01NS096754-02A	382,795	56,541
Chromatin Modifications in GBM-Propagating Cells	R	93-853	R01NS096754-02A	89,818	-
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853	R01NS099460-01	121,888	2,219
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853	R01NS099460-02	233,027	-
Targeting TAZ-driven Oncogenic Signaling in Medulloblastoma	R	93.853	R21NS106407-01	172,591	-
Targeting TAZ-driven Oncogenic Signaling in Medulloblastoma	R	93.853	R21NS106407-01	14,905	13,518
Targeting TAZ-driven Oncogenic Signaling in Medulloblastoma	R	93.853	R21NS106407-02	24,592	-
Defining the Ischemic Penumbra by pH Mapping in Acute Ischemia	R	93.853	R03NS109664-01	64,927	15,010
Defining the Ischemic Penumbra by pH Mapping in Acute Ischemia	R	93.853	R03NS109664-01	3,080	-
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853	R01NS108452-01	167,807	49,991
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853	R01NS108452-01	57,762	57,762
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853	R01NS108452-02	28,254	21,911

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title			Entity	Federal CFDA Number	Pass Through Entity Identification Number	
Cerebrovascular Abnormalities in Huntingtons Disease	R	93.853	R21NS104480-01A1		92,841	27,210
Cerebrovascular Abnormalities in Huntingtons Disease	R	93.853	R21NS104480-01A1		26,975	4,957
Paracrine Angiotensin II Signaling Promotes Medulloblastoma	R	93.853	R21NS101400-01A1		154,544	-
Cortical Functional Connectivity as an Early Biomarker of Recovery in SCI	R	93.853	R21NS104644-01A1		83,469	-
GEWIS Study of Smoking, Hazardous Drinking & Other Health Risk Behaviors	R	93.273	R21AA024404-03		8,311	-
Noninvasive Prediction of Tumor Response to Gemcitabine using MRI	R	93.394	R01CA211087-01A		55,003	-
Noninvasive Prediction of Tumor Response to Gemcitabine using MRI	R	93.394	R01CA211087-02A		262,969	13,180
Noninvasive Prediction of Tumor Response to Gemcitabine using MRI	R	93.394	R01CA211087-03A		123,138	5,203
CEST MRI Assessment of Tumor Vascular Permeability using Non-Labeled Dextrans	R	93.394	R21CA215860-01		37,580	12,386
CEST MRI Assessment of Tumor Vascular Permeability using Non-Labeled Dextrans	R	93.394	R21CA215860-02		86,749	3,920
Preventive Dyadic Intervention to Enhance Communication	R	93.173	R21DC015846-01A1		25	-
Preventive Dyadic Intervention to Enhance Communication	R	93.173	R21DC015846-02A1		232,692	-
MCDD-Creating and Sustaining Diversity Fellowships	R	93.632	90DDUC0047-01		(8,496)	-
National Institute on Aging						
Leveraging energetics to Improve Gait Rehabilitation after Stroke	R	93.866	R21 AG059184-01A1		102,029	20,802
Leveraging energetics to Improve Gait Rehabilitation after Stroke	R	93.866	R21 AG059184-01A1		(193)	-
Total Department of Health and Human Services					16,753,876	3,000,245
<u>The Health Resources and Services Administration</u>						
MCH RESEARCH	R	93.110	T16MC29832-03		144,506	14,906
MCH RESEARCH	R	93.110	T16MC29832-04		23,702	-
Telehealth NetworkGrant Program	R	93.211	H2ARH30299-02		72,328	23,372
Telehealth NetworkGrant Program	R	93.211	H2ARH30299-03		267,303	-
Total Health Resources and Services Administration					507,839	38,278
<u>US Army Medical Research</u>						
Neurovascular Changes Associated with Olfactory Deficits in Early Parkinson's Disease	R	12.420	W81XWH016-PRP-FIA		153,921	-
Alzheimers Research Program	R	12.420	W81XWH1810797		95,767	15,143

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title			Entity	Federal CFDA Number	Pass Through Entity Identification Number	
Total US Army Medical Research					249,688	15,143
Total Research and Development - Direct Awards					17,511,403	3,053,666
Research and Development Cluster- Pass Through Awards						
Johns Hopkins University						
Gene-Environment Interactions for Cortical Development and Schizophrenia	R	93.242		2003126369	34,277	-
Neurobehavioral Correlates of Frustration in Children with ADHD	R	93.242		2002610904	2,184	-
Neurobehavioral Correlates of Frustration in Children with ADHD	R	93.242		2002610904	21,096	-
Neurobehavioral Correlates of Frustration in Children with ADHD	R	93.242		2002610904	5,517	-
Somatosensory Inhibitory Dysfunction in Autism Spectrum Disorder	R	93.242		2003046760	122,931	-
Somatosensory Inhibitory Dysfunction in Autism Spectrum Disorder	R	93.242		2003046760	117,925	-
Somatosensory Inhibitory Dysfunction in Autism Spectrum Disorder	R	93.242		2003046760	102,968	-
Somatosensory Inhibitory Dysfunction in Autism Spectrum Disorder	R	93.242		2003046760	360	-
Investigation of Cerebellar Involvement in Cognitive Function	R	93.242		2002590758	1,626	-
Investigation of Cerebellar Involvement in Cognitive Function	R	93.242		2002590758	14,568	-
Thalamic Connectivity in Recent Onset Schizophrenia	R	93.242		2002832607	11,781	-
Thalamic Connectivity in Recent Onset Schizophrenia	R	93.242		2002832607	28,201	-
Neuroimaging Epigenetics of Prospective Postpartum Depression	R	93.242		2002412818	18,132	-
Intranasal Insulin Therapy for HIV Associated Neurocognitive Disorders	R	93.242		2003486095	15,198	-
Multimodal Investigation of Inhibitory Dysfunction in Autism	R	93.242		2003902559	44,545	-
HIV-Related Neuroplasticity and Attention to Reward as Predictors	R	93.279		2003097253	62,660	-
Measurement of Persisting Changes in Emotional Brain Functioning	R	93.279		2003192503	11,866	-
High-Specificity Imaging Agents for Aggressive Prostate Cancer	R	93.394		2003179660	904	-
High-Specificity Imaging Agents for Aggressive Prostate Cancer	R	93.394		2003179660	4,619	-
Centers for Autism & Developmental Disabilities Research	R	93.073		2001438612	228,221	-
Excitotoxicity in Circulatory Arrest-Brain Injury	R	93.837		2002405038-2002405090	1,444	-
Excitotoxicity in Circulatory Arrest-Brain Injury	R	93.837		2002405038-2002405090	60,494	-
Computational Assessment of Galectin-3 Significance in Heart Failure	R	93.837		2003534038	67,223	-
Computational Assessment of Galectin-3 Significance in Heart Failure	R	93.837		2003534038	1,482	-
Functional & Molecular Properties of PAX7	R	93.846		2003341654	10,638	-
Functional & Molecular Properties of PAX7	R	93.846		2003341654	69,916	-

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Pass Through Entity Identification Number	
Functional & Molecular Properties of PAX7	R	93.846	2003341654	5,382 -
Dual-Mode MRI for In Vivo Sensing of Microcapsule Stability	R	93.847	2002965183	(12,313) -
Dual-Mode MRI for In Vivo Sensing of Microcapsule Stability	R	93.847	2002965183	22,429 -
Neurobiologic Alterations in Bariatric Surgery	R	93.847	2003133682	2,776 -
Dendrimer Therapies for Treatment of Rett Syndrome	R	93.853	2003234282	(210) -
Dendrimer Therapies for Treatment of Rett Syndrome	R	93.853	2003234282	2,430 -
Development of MRI Microvascular Biomarkers	R	93.853	2003335096	19,048 -
A Multimodal MRI Approach in the Neurosciences	R	93.853	2003584112	1,161 -
Imaging Neurodegeneration in MS	R	93.853	2003795776	184,450 -
Molecular Imaging of Brain Injury and Repair in NFL Players	R	93.853	2003699689	2,295 -
Development of Dendrimer N Acetylcysteine for the Treatment of Neonatal Brain Injury	R	93.853	2004023957	12,441 -
Development of MRI Microvascular Biomarkers in Cognitive Impairment and Dementia	R	93.853	2003986087	84,830 -
Lymphocyte CpG Methylation Changes and Brain Pathology in Restless Leg Syndrome	R	93.853	2004063802	15,468 -
Advanced MRI Methods to Image Vascular Physiology w/ Respiratory Manipulations	R	93.853	2002903044	(2,763) -
Advanced MRI Methods to Image Vascular Physiology w/ Respiratory Manipulations	R	93.853	2002903044	(11,369) -
Novel Strategies to Enhance Motor Function After Stroke	R	93.865	2002876504	27,461 -
Adult Biomarkers in Neonatal Brain Injury	R	93.865	2003671299	8,182 -
Adult Biomarkers in Neonatal Brain Injury	R	93.865	2003671299	61,950 -
CSA as a Preventable Public Health Problem	R	93.865	2004209564	18,715 -
Biomarkers of Cognitive Decline Among Normal Individual: the Biocard Cohort	R	93.866	2002373351	(783) -
Biomarkers of Cognitive Decline Among Normal Individual: the Biocard Cohort	R	93.866	2002373351	79,561 -
Alzheimers Disease Neuroimaging Initiative	R	93.866	2003373473	(2,812) -
Alzheimers Disease Neuroimaging Initiative	R	93.866	2003373473	5,333 -
Alzheimers Research	R	93.866	2002582670	37,027 -
Longitudinal Molecular Imaging of Neuropathology	R	93.866	2003816131	7,466 -
Longitudinal Molecular Imaging of Neuropathology	R	93.866	2003816131	11,732 -
Brain Oxygen Consumption as an MRI Biomarker	R	93.866	2003950256	26,204 -
Neural Network Connectivity of Financial Capacity in Mild Cognitive Impairment	R	93.866	2003527906	6,950 -
Imaging Platform and Computational HARDI Atlas of the Human Hippocampus	R	93.866	2003986054	800 -
Neurometabolic Profil of Mild Cognitive Impairment Using Multiplexed Edited MRS	R	93.866	2004031612	4,800 -
Neurometabolic Profil of Mild Cognitive Impairment Using Multiplexed Edited MRS	R	93.866	2004031612	5,866 -
Contribution of Cerebral Iron Load to Elderly Individuals with High Risk for Alzheimers	R	93.866	2004149879	8,470 -
Multi-Modal Magnetic Resonance Imaging in Progressive Supranuclear Palsy	R	93.866	2004149785	2,183 -

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Pass Through Entity Identification Number	
Amide Proton Transfer (APT) MRI of Brain Tumors at 3T	R	93.286	2003130538	(383) -
Neurodegenerative and Neurodevelopmental Subcortical Shape Diff	R	93.286	2003386771	22,911 -
Neurodegenerative and Neurodevelopmental Subcortical Shape Diff	R	93.286	2003386771	26,699 -
Neurodegenerative and Neurodevelopmental Subcortical Shape Diff	R	93.286	2003386771	32,469 -
Simultaneous Hadamard Editing of GABA and Glutathione	R	93.286	2003385023	1,067 -
Label-Free Imaging Research for Technical Innovations	R	93.286	2003464965	8,369 -
Label-Free Imaging Research for Technical Innovations	R	93.286	2003464965	2,826 -
Resource for Molecular Imaging agents in Precision Medicine	R	93.286	2003638047	(3,793) -
Resource for Molecular Imaging agents in Precision Medicine	R	93.286	2003638047	99,817 -
Resource for Molecular Imaging agents in Precision Medicine	R	93.286	2003638047	945 -
Universal Edited MRS at 3T	R	93.286	2003941240	905 -
Hardening and Scaling Core Genomics Software	R	93.859	2003129512	9,134 -
Hardening and Scaling Core Genomics Software	R	93.859	2003129512	9,433 -
Investigating Air Pollution Effects on the Developing Brain and ASD	R	93.113	2003188501	5,170 -
Investigating Air Pollution Effects on the Developing Brain and ASD	R	93.113	2003188501	25,152 -
Stress and Chronic Alcohol Interactions	R	93.273	2003325699	6,504 -
Stress and Chronic Alcohol Interactions	R	93.273	2003325699	14,835 -
JH - Center for Excellence in Regulatory Science and Innovation	R	93.103	2004253590	62,887 -
JH - Center for Excellence in Regulatory Science and Innovation	R	93.103	2004231016	17,870 -
Discovering Network Structure in the Space of Group Level Functional Differences	R	47.040	2004042235	26,763 -
Identifying Model-Based Motor Control Strategies	R	47.041	2004042235	12,332 -
Evaluating the Metabolic Changes Associated with Exercise in MS	R	12.420	2003624821	39,328 -
Total Johns Hopkins University				<u>2,117,176</u> -
University of California				
The Brain Vascular Matt Clinic Research	R	93.853	8397	177 -

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title			Entity	Federal CFDA Number	Pass Through Entity Identification Number	
The Brain Vascular Matt Clinic Research	R	93.853	8397		(39,625)	-
The Brain Vascular Matt Clinic Research	R	93.853	8397		11,894	-
The Brain Vascular Matt Clinic Research	R	93.853	8397		176,665	-
University of Maryland, Baltimore						
Grey Matter Lesions & Neurodegeneration in Multiple Sclerosis	R	93.243	SR00003805		9,261	-
Automated Quantification of Subpail Demyelination	R	93.243	SR00004183		11,443	-
Family Informed Trauma Treatment CTR-FITT	R	93.243	1701143		9,708	-
Family Informed Trauma Treatment CTR-FITT	R	93.243	1701143		33,041	-
University of Maryland, Baltimore						
<i>In Vivo Assessment of Meningeal Inflammation in MS</i>	R	93.853	SR00005281		22,268	-
University of Maryland, Baltimore						
<i>National Center for Child Welfare Curriculum Development</i>	R	93.648	SR00005204		9,996	-
<i>National Center for Child Welfare Curriculum Development</i>	R	93.648	SR00005575		32,598	-
Massachusetts General Hospital						
A CEST MRI Reporter Gene for Image Incolytic Virotherapy	R	93.394	228473		13,673	-
A CEST MRI Reporter Gene for Image Incolytic Virotherapy	R	93.394	228473		2,337	-
University of Massachusetts						
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00463936/RFS2016036		5,043	-
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00463940/RFS2016034		(16,196)	-
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00463938/RFS2016033		(966)	-
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00463938/RFS2016033		9,098	-
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00463938/RFS2016033		26,361	-
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00764093/OSP2018146		16,911	-
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00764092/OSP2018147		145,609	-
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00763694/OSP2018141		16,911	-
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00763696/OSP2018145		147,274	-
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00763696/OSP2018145		28,261	-
Henry Ford Health System						
Plasma Biomarkers of Cerebral Disease in X-Linked Adrenoleukodystrophy	R	93.853	U01AG051412-03		19,930	-

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title			Entity	Federal CFDA Number	Pass Through Entity Identification Number	
University of Michigan						
Thera Hypo After Ped Card Arr	R	93.837	U01HL094345		8,877	-
Baylor University						
Brittle Bone Disorders Consortium of the Rare Disease Clinical Network	R	93.846	U54AR068069		8,483	-
Brittle Bone Disorders Consortium of the Rare Disease Clinical Network	R	93.846	U54AR068069		71,405	-
Drexel University						
An ASF Enriched Risk ECHO Cohort	R	93.310	UG30D023342		65	-
An ASF Enriched Risk ECHO Cohort	R	93.310	UG30D023342		21,891	-
An ASF Enriched Risk ECHO Cohort	R	93.310	UG30D023342		109,140	-
Columbia University						
Identification of Protective Factors for Cognitive Resilience in Adults with Downs Syndrome	R	93.866	4(GG013394-01)		26,577	-
University of South Dakota						
Data and Disability Partnership	R	93.632	90DDUC0024-01-00		1,445	-
Data and Disability Partnership	R	93.632	90DDUC0024-01-00		6,765	-
Virgin Islands University Center						
Data and Disability Partnership	R	93.632	202739		6,090	-
Michigan State University						
Bioengineering a Novel Electromagnetic Perspective Gene	R	93.853	RC108091KKI		21,722	-
Leland Stanford Junior University						
Child Health and Human Development Extramural Research	R	93.865	61687287-47273		5,920	-
Leland Stanford Junior University						
Effort of Vitamin D3 on Markers of Oxidative Stress in Boys with X Linked ALD	R	93.853	61849619-112050		328	-
Partners Healthcare						
Oxidative Stree and Bipolar Disorder Trajectories	R	93.242	11614		7,613	-
Total Research and Development Cluster - Pass Through Awards					3,105,169	-

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title				Entity	Federal CFDA Number	Pass Through Entity Identification Number	
Research and Development Cluster - Total Awards						20,616,572	3,053,666
Other Programs - Direct Awards							
Department of Health and Human Services						-	-
Children's Hospital Graduate Medical Education	H	93.255		338-002		493,212	-
Subtotal DHHS CFDA 93.255						493,212	-
Administration for Children and Families							
Developmental Disabilities	H	93.632		90DD0707/04		-	-
Developmental Disabilities	H	93.632		90DD0707/04		570,000	-
Developmental Disabilities	H	93.632		90DD0707/04		88	-
Subtotal ADD CFDA 93.632						570,088	-
Total Department of Health and Human Services						1,063,300	-
The Health Resources and Services Administration							
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		(943)	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		111,064	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		98,073	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		13,803	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		23,587	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		14,212	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		89,720	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		14,145	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		50,778	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		52,329	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		3,249	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		8,683	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		36,174	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		25,247	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		25,026	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		14,122	-
MCH Training Program in Neurodevelopment Disabilities	H	93.110		2 T73 MC17245-09-00		224,340	-
Subtotal MCH Training Program CFDA 93.110						803,609	-
Total The Health Resources and Services Administration						803,609	-
United States Department of Education							
Efficacy Trial of EarlyAchievements Comp Intervention Preschoolers with Autism	R	84.324A		R 324 A160228		311,188	-
Efficacy Trial of EarlyAchievements Comp Intervention Preschoolers with Autism	R	84.324A		R 324 A160228 JHU SUB		264	264
Efficacy Trial of EarlyAchievements Comp Intervention Preschoolers with Autism	R	84.324A		R 324 A160228 DREXEL SUB		19,612	19,612

Kennedy Krieger Institute, Inc. and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title			Entity	Federal CFDA Number	Pass Through Entity Identification Number	
Efficacy Trial of EarlyAchievements Comp Intervention Preschoolers with Autism	R	84.324A	R 324 A160228		673,715	-
Efficacy Trial of EarlyAchievements Comp Intervention Preschoolers with Autism	R	84.324A	R 324 A160228 JHU SUB		7,204	7,204
Development of an Intervention for Center-Based Early Childhood Education	R	84.324A	R 324 A180085		297,571	-
Subtotal United States Department of Education CFDA 84.324A					1,309,554	27,080
Total Other Programs - Direct Awards					3,176,463	27,080
Other Programs - Pass Through Awards						
Governor's Office Of Crime Control & Prevention						
Underserved Victims	C	16.575	1299		76,537	-
Underserved Victims	C	16.575	1299		4,449	-
Underserved Victims	C	16.575	1299		224,943	-
Subtotal Governor's Office CFDA 16.575					305,929	-
Maryland Department of Education						
School Breakfast Program	C	10.553	9962		32,170	-
Subtotal School Breakfast Program CFDA 10.553					32,170	-
School Lunch Program	C	10.555	9962		78,501	-
Subtotal School Lunch Program CFDA 10.555					78,501	-
Total Child Nutrition School Program					110,671	-
Improving Equity & Access & Opportunity for Students w/ Disabilities	R	84.027	180564		12,108	-
Providing Technical Assistance to the Eastern Shore of Maryland	R	84.027	190323		107,807	-
Implementing Models of Best Practice to Improve Outcomes	R	84.027	190322		65,790	-
Subtotal Assistance to the State for Education Students with Disabilities CFDA 84.027					185,705	-
Preschool Development	C	84.419	180565		85,070	-
Preschool Development	C	84.419	190610		181,144	-
Preschool Development	C	84.419			7	-
Subtotal MSDE CFDA 84.419					266,221	-
Project 4C	C	93.434	191621		17,392	-
Subtotal MSDE CFDA 93.434					17,392	-
Pact: World Of Care Child Care Center	P	84.173	180782		8,972	-
Pact: World Of Care Child Care Center	P	84.173	180540		785	-
Pact: World Of Care Child Care Center	P	84.173			113,725	-
Pact: World Of Care Child Care Center	P	84.173	190384		11,356	-
Pact: Helping Children w/Special Needs Therapeutic Nursery -YMCA	P	84.173	180785		9,953	-
Pact: Helping Children w/Special Needs Therapeutic Nursery -YMCA	P	84.173	190604		114,766	-
Subtotal PACT CFDA 84.173					259,557	-

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title			Entity	Federal CFDA Number	Pass Through Entity Identification Number	
<i>Total Maryland Department of Education</i>					839,546	-
Maryland Developmental Disabilities Council						
Enhancing Advocacy & Public Policy Work Project	H	93.630		17-QA-01	22,275	-
Enhancing Advocacy & Public Policy Work Project	H	93.630		18-QA-01	11	-
Enhancing Advocacy & Public Policy Work Project	H	93.630		19-QA-01	75,639	-
Nurse Consultation and Coaching Demonstration Project	H	93.630		19-CC-01	15,998	-
<i>Subtotal Maryland Developmental Disabilities Council CFDA 93.630</i>					113,923	-
Maryland Department of Health and Mental Hygiene						
Genetics Laboratory	H	93.994		PHPA-G2084	38,329	-
Within My World	P	93.994		FH795CSN/PHPA-G-1165	400,000	-
Enhancing Child Care For Children	C	93.994		MR554 MFC	422,987	-
<i>Subtotal DHMH CFDA 93.994</i>					861,316	-
<i>Total Maryland Department of Health and Mental Hygiene</i>					975,239	-
Maryland Family Network						
Southeast Baltimore EHS	C	93.600		362	4,125	-
Southeast Baltimore EHS	C	93.600		362	10,049	-
Maryland Family Network	P	93.600		3034	(710)	-
Maryland Family Network	P	93.600		3034	(150)	-
Maryland Family Network	P	93.600		3034	45,009	-
Maryland Family Network	P	93.600		3034	245,244	-
Maryland Family Network	P	93.600		3034	10,116	-
Early Head Start Center	C	93.600		650	181,336	-
Early Head Start Center	C	93.600		650	453,923	-
Early Head Start Center	C	93.600		650	240,520	-
<i>Subtotal Maryland Family Network CFDA 93.600</i>					1,189,462	-
Baltimore Mental Health Systems						
Therapeutic Nursery	P	93.000		POS#40	154,500	-
<i>Subtotal Baltimore Mental Health Systems CFDA 93.000</i>					154,500	-
Baltimore City						
Baltimore City Infants & Toddlers Program	P	84.181A		CO#38176	46,124	-
Baltimore City Infants & Toddlers Program	P	84.181A		CO#38177	58,417	-
Baltimore City Infants & Toddlers Program	R	84.181A		CO#37753	51,582	-
<i>Subtotal Baltimore City CFDA 84.181A</i>					156,123	-
<i>Total Baltimore City</i>					156,123	-

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2019

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Pass Through Entity Identification Number
Total Other Programs- Pass Through Awards			3,620,799 -
Total Other Programs- Total Awards			6,797,262 27,080
Total Expenditures of Federal Awards			\$ 27,413,834 \$ 3,080,746

Kennedy Krieger Institute, Inc. and Affiliates
Affiliates Notes to Schedule of Expenditures of Federal Awards
Year Ended June 30, 2019

1. BASIS OF PRESENTATION

The accompanying combined Schedule of Expenditures of Federal Awards (the "Schedule") includes the federal grant transactions of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute") and includes Federal Awards made to the following corporate entities: Kennedy Krieger Children's Hospital, Inc., Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Kennedy Krieger Education & Community Services, Inc. and PACT: Helping Children with Special Needs, Inc. under programs of the federal government for the year ended June 30, 2019. These corporate entities are denoted on the Schedule as follows:

R – Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

H – Kennedy Krieger Children's Hospital, Inc.

C – Kennedy Krieger Education & Community Services, Inc.

P – PACT: Helping Children with Special Needs, Inc.

	Total Federal Expenditures	Passed to SubRecipients
R - Hugo W. Moser Research Institute at Kennedy Krieger Inc.	\$ 22,163,413	\$ 3,080,746
C - Kennedy Krieger Education & Community Services, Inc.	2,013,153	-
H – Kennedy Krieger Children's Hospital, Inc.	2,019,161	-
P - PACT: Helping Children with Special Needs, Inc.	1,218,107	-
	<u>\$ 27,413,834</u>	<u>\$ 3,080,746</u>

Because the Schedule presents only a selected portion of the operations of the Institute, it is not intended to and does not present the financial position, results of operations and non-operating activity, or cash flows of the Institute. Negative amounts reflect adjustments made to expenditures reported in prior years in the normal course of business.

For purposes of the Schedule, federal awards include all awards in the form of grants, contracts, and similar agreements entered into directly between the Institute and agencies and departments of the federal government, or non-federal pass-through entities. Federal CFDA and pass-through identification numbers are included when available.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Schedule reflects federal award program expenditures recognized on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. The Institute has not elected to use the 10% de minimis rate for indirect costs. Indirect costs are billed based upon negotiated and budgeted rates.

Part II
Reports on Compliance and Internal Control



**Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance
and Other Matters Based on an Audit of Financial Statements Performed in Accordance with
Government Auditing Standards**

To the Board of Directors of
Kennedy Krieger Institute, Inc. and Affiliates:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards issued by the Comptroller General of the United States, the consolidated financial statements of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute"), which comprise the consolidated balance sheet as of June 30, 2019, and the related consolidated statements of operations and changes in net assets and cash flows for the year then ended, and have issued our report thereon dated September 25, 2019.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Institute's internal control over financial reporting ("internal control") to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, we do not express an opinion on the effectiveness of the Institute's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Institute's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Baltimore, Maryland
September 25, 2019



**Report of Independent Auditors on Compliance with Requirements
That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over
Compliance in Accordance with the Uniform Guidance**

To the Board of Directors of
Kennedy Krieger Institute, Inc. and Affiliates:

Report on Compliance for Each Major Federal Program

We have audited Kennedy Krieger Institute Inc. and Affiliates (the "Institute") compliance with the types of compliance requirements described in the OMB Compliance Supplement that could have a direct and material effect on each of the Institute's major federal programs for the year ended June 30, 2019. The Institute's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of the Institute's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Institute's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the Institute's compliance.

Opinion on Each Major Federal Program

In our opinion, the Institute complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2019.



Report on Internal Control Over Compliance

Management of the Institute is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Institute's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Institute's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Baltimore, Maryland
November 7, 2019

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Findings and Questioned Costs
Year Ended June 30, 2019

Part III

Schedule of Findings and Questioned Costs

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Findings and Questioned Costs
Year Ended June 30, 2019

Section I – Summary of Auditor’s Results

Financial Statements

Type of auditor’s report issued: Unmodified

Internal control over financial reporting:

Material weakness(es) identified? No

Significant deficiency(ies) identified that are
not considered to be material weaknesses? None Reported

Noncompliance material to financial statements noted? No

Federal Awards

Internal control over major programs:

Material weakness(es) identified? No

Significant deficiency(ies) identified that are not considered
to be material weaknesses? None Reported

Type of auditor’s report issued on compliance for major programs: Unmodified

Any audit findings disclosed that are required to be reported in
accordance with Uniform Guidance? No

Identification of major programs:

<u>Name of Federal Program or Cluster</u>	<u>CFDA Number(s)</u>
Research and Development Cluster	Various
Maternal and Child Health Services Block Grant to the States	93.994
Head Start	93.600
Crime Victim Assistance	16.575
Dollar threshold used to distinguish between type A and type B programs:	\$822,415

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Findings and Questioned Costs
Year Ended June 30, 2019

Section II - Financial Statement Findings

There were no matters reported.

Section III - Federal Award Findings and Questioned Costs

There are no matters to report.

Part IV

Summary Schedule of Prior Audit Findings

Kennedy Krieger Institute, Inc. and Affiliates
Summary Schedule of Prior Audit Findings
Year Ended June 30, 2019

Section II - Financial Statement Findings

There were no matters reported.

Section III - Federal Award Findings and Questioned Costs

There are no matters to report.